Introduction

IJO

International Journal of Oncology

1019-6439 1791-2423

D.A. Spandidos

10.3892/ijo.2018.4660

ijo-54-02-0600

Articles

Potential ceRNA networks involved in autophagy suppression of pancreatic cancer caused by chloroquine diphosphate: A study based on differentially-expressed circRNAs, lncRNAs, miRNAs and mRNAs

Wei

Dan-Ming

1* Jiang

Meng-Tong

1* Lin

Peng

2 Yang

Hong

2 Dang

Yi-Wu

1 Yu

Qiao

1 Liao

Dan-Yu

1 Luo

Dian-Zhong

1 Chen

Gang

1Department of Pathology 2Department of Medical Ultrasonics, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China

Correspondence to: Professor Gang Chen or Professor Dian-Zhong Luo, Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China, E-mail: chengang@gxmu.edu.cn, E-mail: 13878802796@163.com *

Contributed equally

02 2019

10 12 2018

54 2 600 626 14 04 2018 19 10 2018

2019

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Autophagy has been reported to be involved in the occurrence and development of pancreatic cancer. However, the mechanism of autophagy-associated non-coding RNAs (ncRNAs) in pancreatic cancer remains largely unknown. In the present study, microarrays were used to detect differential expression of mRNAs, microRNAs (miRNAs), long ncRNAs (lncRNAs) and circular RNAs (circRNAs) post autophagy suppression by chloroquine diphosphate in PANC-1 cells. Collectively, 3,966 mRNAs, 3,184 lncRNAs and 9,420 circRNAs were differentially expressed. Additionally, only two miRNAs (hsa-miR-663a-5p and hsa-miR-154-3p) were underexpressed in the PANC-1 cells in the autophagy-suppression group. Furthermore, miR-663a-5p with 9 circRNAs, 8 lncRNAs and 46 genes could form a prospective ceRNA network associated with autophagy in pancreatic cancer cells. In addition, another ceRNA network containing miR-154-3p, 5 circRNAs, 2 lncRNAs and 11 genes was also constructed. The potential multiple ceRNA, miRNA and mRNA associations may serve pivotal roles in the autophagy of pancreatic cancer cells, which lays the theoretical foundation for subsequent investigations on pancreatic cancer.

pancreatic cancer autophagy ceRNA circRNA lncRNA chloroquine diphosphate

Introduction

Pancreatic cancer is a highly aggressive and fatal malignancy, with stably high incidence and mortality for the past 30 years globally (1-4). Patients with pancreatic adenocarcinoma account for ~85% of all patients with pancreatic cancer and have a poor prognosis, compared with patients with other common solid tumors (2,5-9). Pancreatic cancer is primarily treated through surgical resection, whereas postoperative patients and patients with advanced disease are frequently subjected to adjuvant therapies with radiotherapy, chemotherapy, and a combination of radiotherapy and chemotherapy that are associated with high recurrence rates and poor treatment effectiveness (10). The recent development of and research into molecular targeted drugs have great significance for the early diagnosis and prognosis of malignant tumors, and have ushered a new era of tumor therapy (11-15). However, the overall treatment effect of these drugs remains poor, and further investigation is required (16).

Autophagy is a process by which eukaryotic cells undergo self-degradation of intracellular damaged macromolecular proteins and organelles (17,18). Autophagy at the physiological level is necessary to maintain the stability of the internal environment, and the occurrence of a variety of diseases, including inflammation, tumors and degenerative diseases, is frequently accompanied by an abnormal autophagic level (19-25). Currently, well-characterized, autophagy-associated proteins include Beclin 1, microtubule-associated-protein-1-light-chain-3 (LC3) and P62, and well-studied pathways include mechanistic target of rapamycin (mTOR) and phosphoinositide 3-kinase (PI3K) pathways (26,27).

Recently, the important role of autophagy in tumors has been recognized (19,28). Studies demonstrated that pancreatic cancer cells have an increased autophagy level, compared with other tumor cells (29-34). The growth of PDAC had a distinct dependence on autophagy in vivo and in vitro (35). Inhibition of autophagy is effective for the treatment of pancreatic cancer through animal experiments (36). Another study revealed that autophagy can be activated by gemcitabine and ionizing radiation in the treatment of pancreatic cancer cells, and activated autophagy serves a role in cancer suppression (37). However, whether autophagy promotes the occurrence, development and prognosis of pancreatic cancer is controversial (38). Therefore, the role of autophagy in the occurrence, development, prognosis and treatment of pancreatic cancer and its mechanism requires further examination.

mRNA is a single-stranded RNA that is transcribed using one of the DNA chains as the template and carries the genetic information that guides protein synthesis. Thus, mRNA occupies an important position in the heredity dogma (39). mRNA serves a key role in various human diseases and is involved in autophagy pathways (40,41); for example, signal transducer and activator of transcription 3 could inhibit autophagy in pancreatic cancer cells (42) and ubiquitin specific peptidase 1 regulates autophagy by targeting Unc-51 like autophagy activating kinase 1 (ULK1) (43). Non-coding RNA (ncRNA) refers to RNA that does not encode a protein and includes ribosomal RNA (rRNA), transfer RNA (tRNA), small nuclear RNA (snRNA), long ncRNA (lncRNA), microRNA (miRNA) and circular RNA (circRNA) (44-50). The involvement of lncRNAs and miRNAs in cancer has been studied intensively, whereas the potential significance of circRNAs in tumors has attracted attention over the last two years (51). The post-transcriptional levels of circRNAs serve a notable regulatory role in gene expression (52). Furthermore, the sponge effect of circRNAs on miRNAs is an important mechanism (53). circRNAs can contain multiple miRNA binding sites, and attract miRNAs effectively to reduce miRNA-mediated mRNA inhibition (54-56). Based on the interaction between these three types of ncRNAs and the current research status in pancreatic cancer, it was considered that an investigation of the effect of lncRNAs and circRNAs as competitive endogenous RNAs (ceRNAs) on the targeting of miRNAs in the development of pancreatic cancer is beneficial.

Recently, the number of autophagy-associated lncRNAs has been determined to be limited (57-60), and investigations on circRNAs and their associations with autophagy have not been reported to date. However, due to autophagy being involved in the occurrence and development of a variety of diseases, including breast (61,62), gastric (63) and lung cancer (64), in the present study, the human pancreatic cancer cell line PANC-1 and gene chip technology was used to detect differential expression of mRNAs, miRNAs, lncRNAs and circRNAs under different autophagy levels, and to investigate the genes associated with autophagy in pancreatic cancer and their underlying molecular mechanisms.

Materials and methods Cell treatment

The human pancreatic cancer cell line PANC-1 was obtained from the Cell Laboratory of Chinese Academy of Sciences (Shanghai, China) and cultured in complete Dulbecco’s modified Eagle’s medium (DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 37°C. Due to chloroquine diphosphate being frequently used as a classic autophagic inhibitor (65,66), the following concentration gradient of chloroquine diphosphate (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) was designed as recommended by the manufacturer’s protocols: 0, 25, 50, 75 and 100 µM. When the number of cells in the culture bottle grew to ~5×10^6, the original medium was replaced by a complete DMEM containing chloroquine diphosphate. Following treating the cells for 12 h at 37°C with the drug, the cellular proteins were immediately extracted using Radioimmunoprecipitation Assay Lysis Buffer (Beyotime Institute of Biotechnology, Haimen, China).

Western blotting

The lysis solution (radioimmunoprecipitation assay buffer:phenylmethylsulfonyl fluoride; 100:1, Beyotime Institute of Biotechnology) was prepared. The protein concentration in the lysate was determined with a bicinchoninic acid kit (Beyotime Institute of Biotechnology), according to the manufacturer’s instructions. Western blotting was performed according to routine procedures, and conducted with a 12% separating gel and a 5% stacking gel. A total of 20 µg protein was added to the glue holes. The electrophoresis condition was set to 120 Ma for 1 h. Following the electrophoresis, the protein was transferred to the polyvinylidene (PVDF) membrane (Beyotime Institute of Biotechnology). Subsequently, the PVDF membrane was placed into the Bull Serum Albumin blocking buffer (Beyotime Institute of Biotechnology) for shaking at 37°C for 2 h. Primary antibodies were incubated at 4°C overnight and secondary antibodies were incubated at room temperature for 2 h. The primary antibodies were LC3 β-specific rabbit polyclonal (1:1,000; cat. no. 18725-1-AP) and P62 mouse monoclonal antibodies (1:2,000; cat. no. 66184-1-Ig), which represented the state of autophagy, and the GAPDH horseradish peroxidase-labeled internal reference antibody (1:10,000; cat. no. HRP-60004), andhe secondary antibodies used were goat anti-mouse IgG (H+L), allopregnanolone conjugate (1:1,000; cat. no. SA00002-1) (all from ProteinTech Group, Inc., Chicago, IL, USA). The gray scale values of the protein bands from the raw image were determined using the ImageJ 1.48 (National Institutes of Health, Bethesda, MD, USA) and the formula Final gray scale value (G) = [G × (target band) − G × (background)] / [G × (internal reference band of the group) − G × (background)]. The data were analyzed using SPSS software 22 (SPSS, Inc., Chicago, IL, USA), and the results were plotted using the GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA).

Sample grouping

Based on the results of the western blotting experiment, the human pancreatic cancer PANC-1 cells treated with 100 µM chloroquine diphosphate were selected as the autophagic inhibition group, and the cells cultured in normal DMEM medium were selected as the control group. Subsequent experiments were compared between the autophagic inhibition group and the control group. Following chloroquine diphosphate treatment, total RNA was prepared using the TRIzol^® reagent (Beyotime Institute of Biotechnology) with three replicates per group.

ceRNA microarray and detection, and statistical analysis of the miRNA chip results

The quality control for the gene analyses in the present study was performed by Shanghai Biotechnology Corporation (Shanghai, China). The starting sample of the microarray test was total RNA, which was analyzed with the NanoDrop ND-2000 spectrophotometer and the Agilent Bioanalyzer 2100 (Agilent Technologies, Inc., Santa Clara, CA, USA) to conduct the quality control assay. Only RNA samples that passed the quality control proceeded to the subsequent microarray experiments. The qualifying sample standards were that the RNA integrity number of each sample was ≥7.0 and that the 28S/18S was ≥0.7.

The ceRNA microarray detection assay included the detection of three types of RNA (lncRNA, circRNA and mRNA). The cutoff values of the differentials were all set to a fold change (FC)>2 or FC<0.5 and P<0.05. The assays and data analyses are described below. The analyses primarily included the normalization of raw data, sample association analysis, screening of genes with differential expression, Gene Ontology (GO) enrichment analysis of the differentially-expressed mRNAs, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis, PANTHER pathway analysis of the differentially-expressed mRNAs, prediction of lncRNA and circRNA target genes, and prediction of lncRNA and circRNA adsorption of miRNAs. GO and KEGG pathway were generated by DAVID (https://david.ncifcrf.gov/) while PANTHER was analyzed using the WebGestalt 2017 tool (http://www.webgestalt.org/option.php). The clinical roles of genes were analyzed through the online database of Gene Expression Profiling Interactive Analysis (GEPIA; http://gepia.cancer-pku.cn/) Which is based on the data obtained from The Cancer Genome Atlas and GTEx. The miRNA microarray analyses primarily included the normalization of raw data, sample association analysis, screening of differentially-expressed miRNAs and prediction of miRNA target genes, which was predicted by 12 online miRNA target prediction databases [DIANA-microTv4.0 (67), DIANA-microT-CDS (68), miRanda-rel2010 (69), mirbridge (70), miRDB4.0 (71), miRMap (72), miRNAMap (73), PicTar2 (74), PITA (75), RNA22v2 (76), RNAhybrid2.1 (77) and Targetscan6.2 (78)] (http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/). The crossed genes from target prediction and differentially-expressed mRNAs were depicted in Compendia expression profiles (Novartis; http://software.broadinstitute.org/gsea/msigdb/annotate.jsp). Network visualization was performed in Cytoscape 3.5.1 (The Cytoscape Consoritum, New York, NY, USA).

The raw data of ceRNA microarray has been deposited in the Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/; accession number GSE115517).

Tissue samples

A total of 31 formalin-fixed paraffin-embedded (FFPE) tissues, including 18 cases of Pancreatic ductal adenocarcinoma and 13 paracancerous tissues, were collected from the Department of Pathology of the First Affiliated Hospital of Guangxi Medical University (Nanning, China) between June 2015 and June 2018. The present study was approved by the Ethics Committee of the First Affiliated Hospital of Guangxi Medical University. All cases were from patients who have not been treated with chemotherapy or radiation prior to resection and have signed informed consent. There were 11 male and 7 female aged 29-77 years (mean age, 56 years) in 18 patients with adenocarcinoma.

RNA extraction and Real-time fluorescent quantitative PCR (RT-qPCR)

According to the user guides provided by the manufacturer, the total RNA of tissues was extracted using an E.Z.N.A.^® FFPE RNA kit (Omega Bio-Tek, Inc., Norcross, GA, USA). The complementary DNA (cDNA) was reverse transcribed through the kit of miRNA First Strand cDNA Synthesis [Tailing Reaction (79,80)] (Sangon Biotech Co., Ltd., Shanghai, China), and RT-qPCR was conducted by applying a MicroRNAs qPCR kit [SYBR^® Green method (81,82)] (Sangon Biotech Co., Ltd.), according to the manufacturer’s protocols, on an ABI Prism 7500 (Applied Biosystems; Thermo Fisher Scientific, Inc.). The temperature of pre-denaturation and denaturation were both set at 95°C, and the temperature of annealing/extension was set at 60°C. Pre-denaturation was conducted for 10min, denaturation for 15 sec and annealing/extension for 60 sec. The number of cycles was set to 40. Subsequently, the expression of miRNA relative to U6 was calculated via the 2^−ΔΔCq method on identical samples (83). The PCR primers included: i) miR-663a-5p for ward, 5′-ATAGGCGGGGCGCCGCGGGAC-3′; ii) miR-154-3p forward, 5′-CCGGGAATCATACACGGTTGA CCTATT-3′; and iii) U6 forward and universal PCR reverse primer were attached to the kits. Their primer sequences are 5′-CTCGCTTCGGCAGCACA-3′ and 5′-AACGCTTCACGA ATTTGCGT-3′, respectively.

Retrieval of data from GEO

Within GEO, ‘pancreas’ or ‘pancreatic’, and ‘adenocarcinoma’, ‘carcinoma’, ‘cancer’, ‘neoplasm’, ‘tumor’, ‘tumour’, ‘neoplas^*’, ‘malignan^*’, ‘PDAC’, ‘OR’, ‘PAAD’ or ‘PC’ were employed as a search strategy in GEO to determine the expression of miR-663a-5p and miR-154-3p. STATA 12.0 (StataCorp LLC, College Station, TX, USA) was applied to estimate the pooled effects, heterogeneity and publication bias.

Statistical analysis

The data of GEO and RT-qPCR were calculated using SPSS 22 software for mean and standard deviation (SD). Continuous data are presented as mean ± SD. The forest plots were produced by Stata 12.0. The heterogeneity test was used to analyze the existence of heterogeneity and the source of the occurrence of heterogeneity (I²>50% or P<0.05 is the existence of heterogeneity). Funnel plots were used for the analysis of publication bias. The comparison between the two groups was performed using two-sample Student’s t-test. The method for differential gene expression analysis in GEPIA was one-way analysis of variance, using pathological stage as variable for calculating differential expression. GEPIA performs overall survival analysis based on gene expression. GO analysis was performed in DAVID tool which used Fisher’s exact test and the techniques of Kappa statistics (84). PANTHER analysis was performed in WebGestalt, which used Hypergeometric and Fisher’s exact tests. P<0.05 was considered to indicate a statistically significant difference.

Results Autophagy following chloroquine diphosphate treatment

The present study design of the whole investigation is depicted in Fig. 1. The LC3-II expression level was significantly reduced in the control group, compared with the group treated with 25 or 100 µM chloroquine diphosphate (P<0.05). However, the P62 expression level was significantly increased in the group treated with 100 µM chloroquine diphosphate, compared with the control group or the groups treated with 25, 50, 75 or 100 µM chloroquine diphosphate (P<0.05). Thus, the 100 µM concentration of chloroquine diphosphate had the greatest significant inhibitory effect on autophagy in human pancreatic cancer PANC-1 cells (Fig. 2).

Quality control of samples for the ceRNA microarray and miRNA microarray chips

Electrophoresis of the RNA samples indicated that the RNA integrity number of each sample was ≥7.0 and that the 28S/18S was ≥0.7, which reached the qualifying sample standards. Thus, the samples were qualified for use in the subsequent experiments.

Assays to identify differentially-expressed mRNAs, lncRNAs, circRNAs and miRNAs

The ceRNA microarray results determined 3,966 differentially-expressed mRNAs in total. The expression levels of 2,445 mRNAs in the PANC-1 cells from the chloroquine diphosphate treatment group (autophagy suppression group) were downregulated and 1,521 mRNAs were upregulated, compared with the control group (Fig. 3). Additionally, 3,184 differentially-expressed lncRNAs were observed, including 1,637 downregulated and 1,547 upregulated (Fig. 4), whereas 9,420 circRNAs were determined to be differentially expressed, including 4,223 downregulated and 5,197 upregulated (Fig. 5). The miRNA microarray results demonstrated that the expression levels of two miRNAs (hsa-miR-663a-5p and hsa-miR-154-3p) were underexpressed in the PANC-1 cells in the autophagy-suppression group, compared with the control group. No upregulated miRNA was determined. The cutoff values of the aforementioned differentials were all set to a fold change>2 or FC<0.5 and P<0.05.

Bioinformatics analysis of the functions of the differentially-expressed mRNAs

GO and KEGG pathway analyses were performed using the DAVID database. The 3,966 differentially-expressed mRNAs in the chloroquine diphosphate treatment group (autophagy suppression group), compared with the control group, were subjected to bioinformatics analysis of their functions. The results demonstrated that these genes were concentrated in the biological processes, molecular functions and cellular components categories in the GO analysis (Table I), and were involved in the regulation of multiple KEGG signaling pathways including pathways in cancer and the mitogen-activated protein kinase signaling pathway (Table II). Of these functions, the involvement of the autophagy-associated pathway (Autophagy) was notable. Additionally, the differentially-expressed genes in this pathway included a number of recognized autophagy-associated genes, including autophagy-related 12 (ATG12), GABA type A receptor associated protein like 1 (GABARAPL1) and ULK2, which were differentially expressed in the present ceRNA microarray results also (Fig. 6). Following analyzing the clinical roles of the three genes via the Gene Expression Profiling Interactive Analysis online database, which is based on the data obtained from The Cancer Genome Atlas and GTEx, it was determined that the expression of ATG12 was upregulated in pancreatic cancer tissue, compared with non-tumor tissue. Furthermore, high expression of ATG12 was associated with significantly reduced survival time (P<0.01). Notably, the expression of ATG12, GABARAPL1 and ULK2 were increased in pancreatic cancer, compared with the control group (Fig. 6). These results validated that these autophagy-associated genes were involved in the onset and progression of pancreatic cancer.

Prediction of target genes of the differentially-expressed miRNAs and the bioinformatics analysis of their functions

These results were integrated with the differentially-expressed mRNAs that were actually measured. The co-expressed genes were subjected to GO and KEGG pathway analyses using the DAVID database.

Prediction of miR-663a-5p target genes and bioinformatics analysis of their functions

A total of 1,726 target genes of miR-663a-5p were detected by at least 6 platforms using the aforementioned 12 online miRNA target gene prediction databases. Following cross-checking with the differentially-expressed genes in the autophagy suppression group derived from chloroquine diphosphate treatment, 462 co-expressed genes were obtained (Fig. 7). These genes were subjected to GO and KEGG pathway analyses. The results demonstrated that these genes were concentrated in the biological processes, molecular functions and cellular components categories in the GO analysis (Fig. 8A, Table III) and were involved in the regulation of multiple KEGG signaling pathways (Table III), including the aldosterone-regulated sodium reabsorption and Wnt signaling pathways (Fig. 8B-D). However, there were no significant pathways determined by PANTHER analysis (P>0.05).

Prediction of miR-154-3p target genes and bioinformatics analysis of their functions

A total of 294 target genes of miR-154-3p were detected by at least 6 programs using the aforementioned 12 online miRNA target gene prediction databases. Following cross-checking with the differentially-expressed genes in the autophagy suppression group derived from chloroquine diphosphate treatment, 294 co-expressed genes were obtained (Fig. 9). These genes were subjected to GO and KEGG pathway analyses. The results demonstrated that these genes were concentrated in the biological processes, molecular functions and cellular components categories in the GO analysis (Fig. 10A, Table IV), and were involved in the insulin signaling, Forkhead Box O (FoxO) signaling and proteoglycans in cancer pathways (Table IV, Fig. 10B-D). Additionally, the results of PANTHER analysis revealed these genes were concentrated in a numbered of pathways, including the p53 pathway by glucose deprivation and the classical gastrin cholecystokinin receptor (CCKR) signaling map (Table V, Fig. 11).

Prediction of ceRNAs of the differentially-expressed miRNAs

Different online platforms were used to predict the target genes of the differentially-expressed miRNAs. The target circRNAs and lncRNAs of the differentially-expressed miRNAs were searched based on the prediction of the target miRNAs of the differentially-expressed circRNAs and lncRNAs revealed by microarray detection, and the differentially-expressed miRNAs that were detected. The ceRNAs that were negatively associated with the expression of the miRNAs were selected.

Prediction of ceRNAs of miR-663a-5p

A total of 21 differentially-expressed circRNAs that targeted miR-663a-5p were determined, of which nine (hsa_circ_0003176, hsa_circ_0048579, hsa_circ_0063706, hsa_circ_0071922, hsa_circ_0078989, hsa_circ_0079319, hsa_circ_0083080, hsa_circ_0089643 and hsa_circ_0090372) indicated negative associations with miR-663a-5p expression. hsa_circ_0071922 had the highest number of binding sites for miR-663a-5p, with six. Simultaneously, 45 differentially-expressed lncRNAs that targeted miR-663a-5p were determined, of which 8 lncRNAs (RP11-59C5.3, RP13-516M14.8, RP11-196G18.24, AJ006995.3, AC024560.2, PPP1R1C, LINC00595 and HAGLROS) were negatively associated with miR-663a-5p expression. All of these lncRNAs had one miR-663a-5p binding site (Table VI). Subsequently, 144 common predicted targets from at least 8 among 12 programs were selected to overlap with the 3,966 differentially-expressed genes following autophagy inhibition. Collectively, 46 potential targets were determined. Thus, a ceRNA hypothesis figure with miR-663a-5p, 9 circRNAs, 8 lncRNAs and 46 genes was depicted in Fig. 12.

Prediction of ceRNAs of miR-154-3p

A total of 6 differentially-expressed circRNAs that targeted miR-154-3p were determined, of which five (hsa_circ_0000156, hsa_circ_0004089, hsa_circ_0006461, hsa_circ_0015157 and hsa_circ_0038665) indicated a negative association with miR-154-3p expression. All of these circRNAs had two miR-154-3p binding sites. Simultaneously, 16 differentially-expressed lncRNAs that targeted miR-154-3p were determined, of which two (RP11-686O6.1 and LINC01140) were negatively associated with miR-154-3p expression. These lncRNAs had one miR-154-3p binding site (Table VI). Similarly to miR-663a-5p, 67 common predicted targets of miR-154-3p from at least 8 among 12 platforms were collected, and then they were intersected into the 3,966 differentially-expressed genes following autophagy suppression. Eventually, 11 potential targets were collected. Hence, a ceRNA hypothesis network with miR-154-3p, 5 circRNAs, 2 lncRNAs and 11 genes was presented (Fig. 13).

Meta-analysis of miR-663a-5p and miR-154-3p expression based on RT-qPCR and GEO data

A comprehensive analysis for the expression of miR-663a-5p and miR-154-3p in pancreatic cancer tissues was performed based on RT-qPCR and GEO data. The combined standardized mean difference (SMD) values of miR-663a-5p was −0.203 [95% confidence interval (CI), −0.675-0.269; Fig. 14A)], which indicated that miR-663a had low expression in pancreatic cancer tissues; however, heterogeneity existed (I²=63.6%; P=0.011; Fig. 14B). Sensitivity analysis and publication bias of miR-663a-5p were depicted in Fig. 14C. The combined SMD values of miR-154-3p was −0.434 (95% CI, −1.079-0.212; Fig. 15A)], which indicated that miR-154-3p had low expression in pancreatic cancer tissues; however, heterogeneity existed (I²=76.0%; P=0.001; Fig. 15B). Sensitivity analysis and publication bias of miR-154-3p were depicted in Fig. 15C.

Discussion

Pancreatic cancer is one of the common malignancy types of the digestive system. Due to the lack of an effective early diagnosis, numerous patients are already in the advanced stage of the cancer when diagnosed (85). Currently, pancreatic cancer treatment remains dominated by surgical resection, which has a low five-year survival rate (86-88). Therefore, there is an urgent requirement for a series of effective markers for pancreatic cancer to change the current status of the poor efficacy of individualized treatment. Recent studies demonstrated that although ncRNAs do not encode proteins, they serve a pivotal role in the regulation of a variety of malignant tumor types, including gastric (89), pancreatic (90), prostate (91) and breast cancer (92). Over the past two years, the extensively investigated ncRNAs, including lncRNAs and miRNAs, and circRNAs, which were newly revealed to have similar regulatory functions, particularly to miRNAs, were indicated to also serve crucial roles (44,93-97). Abnormal expression of a large number of miRNAs has been determined in malignant tumor tissues (98-100). For example, it has been reported that miR-221/222 and miR-15b serve a role in causing malignant tumors (101). Additionally, it was determined that miR-451 and miR-126 have an abnormal expression in lung cancer (102), and the targeted delivery of miRNA therapeutics was a promising strategy for cancer (103). This abnormal expression pattern affects the occurrence, development and prognosis of the tumor by directly regulating the biological functions of the targeted mRNAs (102,104-112). Studies have demonstrated that a variety of miRNAs exhibit abnormal expression patterns in pancreatic cancer cells that affect the occurrence, development and prognosis of pancreatic cancer; for example, the upregulated expression of miR-10b, miR-21, miR23a and miR-27a in pancreatic cancer affects cell growth, proliferation and apoptotic metastasis by targeting programmed cell death 4, BTG anti-proliferation factor 2, neural precursor cell expressed, developmentally downregulated 4-like, phosphatase and tensin homolog, HIV-1 Tat interactive protein 2 and p16 (113-117).

With the increased understanding of the regulatory mechanism of ncRNAs, ceRNAs have attracted increasing attention as important regulators of miRNA activity. ceRNA refers to lncRNAs and circRNAs that suppress miRNA expression through targeted binding to the miRNA, and thus regulate its activity, which affects the development, progression and prognosis of tumors (118-120). Studies have indicated that lncRNA-metastasis associated lung adenocarcinoma transcript 1 can target miR-124 to reduce its expression and activate cyclin-dependent kinase 4, thereby accelerating the progression of breast cancer (121-123). A recent study on pancreatic cancer demonstrated that lncRNA-urothelial cancer associated 1 was overexpressed in pancreatic cancer tissues and reduced miR-135a expression by adsorbing it, thereby inhibiting genes associated with tumor growth and metastasis (124). These examples highlight the significance of the interactions among lncRNAs, miRNAs and mRNAs for cancer diagnosis and treatment.

Therefore, our aim was to mine pancreatic cancer autophagy-associated ceRNAs and miRNAs through assays with ceRNA and miRNA microarrays, respectively, to reveal their targets using bioinformatics methods, construct ceRNA, miRNA and mRNA pathways, predict the potential molecular mechanisms of the ceRNA, miRNA and mRNA pathways in the autophagy of pancreatic cancer, and provide novel ideas and directions for further studies of pancreatic cancer.

Firstly, the differentially-expressed mRNAs were analyzed. The results demonstrated that PANC-1 cells treated with chloroquine diphosphate had multiple differentially-expressed mRNAs, compared with the control group, using the FC value FC>2 or FC<0.5 as the threshold. The bioinformatics analysis of these genes indicated that as the autophagic level changed, the differentially-expressed genes were primarily concentrated in tumor-associated and pancreatic cancer-associated pathways. Notably, the autophagy-associated pathway, in which three genes (ATG12, GABARAPL1 and ULK2) were abnormally expressed when the autophagic level, was inhibited. ATG12 is an autophagy-related protein that has been demonstrated to function as a key autophagy-associated target gene regulated by miR-23b, and suppression of ATG12 significantly increased the radiosensitivity of pancreatic cancer cells, whereas the miR-23b-induced radiosensitivity was eliminated by ATG12 overexpression (125). Studies indicated that ULK served an important role in the autophagy process (126-128). ULK2 and ULK1 are highly homologous, functionally complementary and indispensable for affecting autophagy (129-131). GABARAPL1 is considered as a target of miR-195 and regulates the proliferation, migration, angiogenesis and autophagy of endothelial progenitor cells (132). These three genes (ATG12, GABARAPL1 and ULK2) may serve pivotal roles in the autophagy suppressed by chloroquine diphosphate in pancreatic cancer cells.

To determine relevant miRNAs and elucidate their potential regulatory mechanisms in the autophagy of pancreatic cancer, differentially-expressed miRNAs were analyzed and their target genes were predicted. Subsequently, the results were compared with the target genes detected in the microarray analysis. The co-expressed genes were considered the putative target genes regulated by the abnormally-expressed miRNAs during the autophagy process in pancreatic cancer cells. Bioinformatics analyses were performed on these target genes to identify the signaling pathways and biological processes that were regulated. The results demonstrated that the expression of miR-663a-5p and miR-154-3p was downregulated in the PANC-1 cells treated with chloroquine diphosphate, compared with the control group. miR-663a-5p expression in pancreatic cancer tissues is significantly downregulated and negatively associated with eukaryotic translation elongation factor 1α 2 (eEF1A2) expression due to miR-663 reducing the proliferation and invasion of pancreatic cells by directly targeting eEF1A2 in vitro and in vivo (133). Additionally, miR-663a-5p has been reported to have a low expression in hepatocellular carcinoma (134), non-small cell lung cancer (135) and colorectal cancer (136). Similarly, the present comprehensive analysis indicated that the expression of miR-663a-5p was downregulated in pancreatic ductal adenocarcinoma (PDAC). In the present study, the bioinformatics analyses indicated that the putative autophagy pathways in the pancreatic cancer cells regulated by miR-663a-5p included the aldosterone-regulated sodium reabsorption, Wnt signaling, basal cell carcinoma, fatty acid biosynthesis and PI3K-Akt signaling pathways, of which the Wnt signaling and PI3K-Akt signaling pathways were considered to have a function in the regulation of autophagy (137-143). Currently, whether miR-154-3p is involved in the biological processes of pancreatic cancer cells, including occurrence, development, prognosis and autophagy, remains unknown; however, miR-154-3p was reported to be expressed at a low level in colorectal cancer and was associated with the degree of malignancy of colorectal cancer (144). Similarly, miR-154-3p exhibited low expression in breast cancer and affected the treatment outcome of breast cancer by regulating E2F transcription factor 5 (145). Additionally, the present comprehensive analysis indicated that the expression of miR-154-3p was downregulated in PDAC. Furthermore, the bioinformatics analyses indicated that the putative autophagy pathways in the pancreatic cancer cells regulated by miR-154-3p included the insulin signaling pathway, FoxO signaling, mitogen-activated protein kinase signaling, ErbB signaling, p53 pathway by glucose deprivation and CCKR signaling map pathways. Activation of insulin like growth factor 1 receptor (IGF-1R) signaling antagonizes the decrease in cell viability of human disc cells through the suppression of apoptosis and enhancement of autophagy (146). IGF-1R increases cell viability during hypoxia, which may be dependent on promoting autophagy by suppressing the PI3K/Akt/mTOR signaling pathway (147). The present study demonstrated that a number of genes, including suppressor of cytokine signaling 1 (SOCS1), plasma membrane intrinsic protein 3 (PIP3) and serine/threonine protein phosphatase type 1 α (PP1), which were involved in the insulin signaling pathway, were abnormally expressed when the autophagic level was decreased. Overexpression of SOCS1 suppressed the PI3K/PIP3/Akt signaling pathway with the subsequent PP1 activation, which has been demonstrated to induce autophagy (148,149). Autophagy is inhibited under the condition of oxygen-glucose deprivation (150). Therefore, we hypothesized that miR-154-3p influences the key genes in the insulin signaling or p53 pathways by glucose deprivation, thereby affecting autophagy. Additionally, due to the involvement of CCKR signaling in pancreatic enzyme secretion (151,152), miR-154-3p may serve a key role in the secretion process. Therefore, the data in the present study will provide novel directions for the investigation of pancreatic cancer and its autophagy.

To elucidate which genes inhibited the miRNAs regulating the autophagy of pancreatic cancer cells through competitive binding, potential target associations between circRNA and miRNA, and between lncRNA-miRNA were predicted based on the competitive expression of ceRNA and miRNA. When these results were combined with the differentially-expressed circRNAs and lncRNAs under different autophagic levels detected by the microarrays, numerous ceRNAs that exhibited target associations with miR-663a-5p and miR-154-3p, and negative associations with the expression of the targeted miRNAs under the same changes in the autophagic level were determined. AC024560.2 is an effective lncRNA residing on chromosome 3 that can be used to predict the metastasis of early cervical cancer to lymph nodes (153). In the present study, AC024560.2 was determined to competitively bind to miR-663a-5p and thus regulate the autophagic level of pancreatic cancer cells by inhibiting the expression of this miRNA. For the other ceRNAs, their associations with tumors have not been reported, and further investigations are required.

Since the molecular mechanisms of tumor occurrence and development are complex and the numerous different physiological processes, including differentiation (154) and aging (155), are frequently accompanied by an aberrant autophagic level (156,157), it is not surprising that the interference of autophagy is determined to be one of the therapeutic methods for tumors. The growth of PDAC could be repressed by hydroxychloroquine in vivo and in vitro (158). PDAC was dependent on autophagy and the use of an autophagy inhibitor may become the breakthrough point of treatment (35). However, in the treatment of PDAC with gemcitabine, a high concentration of gemcitabine is required following adding autophagy inhibitors (37). Therefore, autophagy may serve a dual role in the development of PDAC. Investigating the ceRNA network following inhibiting autophagy, of which these genes may serve role in inhibiting autophagy or promoting autophagy, will provide novel ideas for determining new ways to treat pancreatic cancer. On this basis, the biological function and action mechanism of these two miRNAs will be investigated in further studies.

In summary, the miRNAs that were significantly associated with the autophagy of pancreatic cancer included miR-663a-5p and miR-154-3p. These miRNAs were used as the intermediate regulatory sites, upstream to which multiple putative ceRNAs, including AC024560.2, were present and downstream to multiple targeted regulatory genes, including ATG12 and ULK1. The expression of these miRNAs was regulated through ceRNA, miRNA and mRNA interactions, which could serve important regulatory roles in pancreatic cancer autophagy.

In conclusion, autophagy serves an important role in the development and progression of various malignant tumor types, including lung (159), gastric (160) and renal cancer (161). The investigation of differentially-expressed genes in pancreatic cancer cells under different autophagic levels not only clarifies the regulatory mechanism of the autophagic process in pancreatic cancer cells, but also provides novel ideas for the effective diagnosis and treatment of pancreatic cancer. In the present study, microarray technology was employed to confirm that the change in the autophagic level of pancreatic cancer cells was accompanied by various differentially-expressed genes. Following establishing multiple ceRNA, miRNA and mRNA associations, there is more reason to consider that these genes will serve important roles in the diagnosis and treatment of pancreatic cancer, and thus lay the theoretical foundation for subsequent investigations on pancreatic cancer while indicating new research directions. Subsequently, the regulatory functions of these genes at the cellular and tissue levels will be investigated and their specificity and accuracy will be further validated through a series of in vivo and in vitro experiments.

Funding

The study was supported by the funds of the National Natural Science Foundation of China (grant no. NSFC81560448), the Natural Science Foundation of Guangxi, China (grant no. 2016GXNSFBA380039), Medical Excellence Award Funded by the Creative Research Development Grant from the First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University Training Program for Distinguished Young Scholars, and the Promoting Project of Basic Capacity for University Young and Middle-aged Teachers in Guangxi (grant no. KY2016LX031). The funders had no role in the study design, the data collection and analysis, the decision to publish, or the preparation of the manuscript.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

DMW and MTJ wrote the paper, performed the experiments and conducted bioinformatics analysis. PL, HY and YWD wrote the paper and conducted bioinformatics analysis. QY and DYL conducted bioinformatics analysis and statistical data analysis. DZL and GC designed the project, supervised the experiments and corrected the draft.

Ethics approval and consent to participate

The present study was approved by the Ethics Committee of the First Affiliated Hospital of Guangxi Medical University, and all patients provided signed informed consent.

Patient consent for publication

Consent for the publication of the pathological data was obtained from all patients who were involved in the present study.

Competing interests

The authors declare that they have no competing interests.

Acknowledgments

The authors would like to thank all publicly available data used in the present study.

Abbreviations

rRNA

ribosomal RNA

tRNA

transfer RNA

snRNA

small nuclear RNA

lncRNA

long non-coding RNA

miRNA

microRNA

circRNA

circular RNA

ceRNAs

competitive endogenous RNAs

RIN

RNA integrity number

Gene Ontology

KEGG

Kyoto Encyclopedia of Genes and Genomes

GEO

Gene Expression Omnibus

ATG12

autophagy-related 12

References 1

Ryan

Hong

Bardeesy

Pancreatic adenocarcinoma

N Engl J Med371214021412014

10.1056/NEJMra1404198

25427123

Swords

Firpo

Scaife

Mulvihill

Biomarkers in pancreatic adenocarcinoma: Current perspectives

OncoTargets Ther9745974672016

10.2147/OTT.S100510

Siegel

Miller

Jemal

Cancer Statistics, 2017

CA Cancer J Clin677302017

10.3322/caac.21387

28055103

Siegel

Miller

Jemal

Cancer statistics, 2018

CA Cancer J Clin687302018

10.3322/caac.21442

29313949

Song

Wang

Lan

Zhang

Expression of Notch receptors and their ligands in pancreatic ductal adenocarcinoma

Exp Ther Med1653602018

29896227

5995048

Gao

Identification of a novel alternative splicing transcript variant of the suppressor of fused: Relationship with lymph node metastasis in pancreatic ductal adenocarcinoma

Int J Oncol49261126192016

10.3892/ijo.2016.3753

27840902

Zhang

Yan

Yang

Wang

Cao

The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer: HER14 protein expression and prognosis in pancreatic cancer

BMC Cancer169102016

10.1186/s12885-016-2889-6

Hao

Wang

Liu

Zhang

Duan

Circular RNA Expression Profile of Pancreatic Ductal Adenocarcinoma Revealed by Microarray

Cell Physiol Biochem40133413442016

10.1159/000453186

27997903

Zhu

Staley

Kooby

El-Rays

Mao

Yang

Current status of biomarker and targeted nanoparticle development: The precision oncology approach for pancreatic cancer therapy

Cancer Lett3881391482017

10.1016/j.canlet.2016.11.030

5318282

Kocaturk

Gozuacik

Crosstalk Between Mammalian Autophagy and the Ubiquitin-Proteasome System

Front Cell Dev Biol61282018

10.3389/fcell.2018.00128

30333975

6175981

Hong

Czito

Willett

Palta

A current perspective on stereotactic body radiation therapy for pancreatic cancer

OncoTargets Ther9673367392016

10.2147/OTT.S99826

Marsoner

Haybaeck

Csengeri

Waha

Schagerl

Langeder

Mischinger

Kornprat

Pancreatic resection for intraductal papillary mucinous neoplasm - a thirteen-year single center experience

BMC Cancer168442016

10.1186/s12885-016-2887-8

Kang

Jang

Kim

Surgical resection of pancreatic head cancer: What is the optimal extent of surgery

Cancer Lett3822592652016

10.1016/j.canlet.2016.01.042

26828131

Ellerhoff

Berchtold

Venturelli

Burkard

Smirnow

Wulff

Lauer

Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus

Int J Oncol49193119442016

10.3892/ijo.2016.3675

27601235

Zuo

Sheng

Xia

Ouyang

ISG15 in the tumorigenesis and treatment of cancer: An emerging role in malignancies of the digestive system

Oncotarget774393744092016

10.18632/oncotarget.11911

27626310

5342061

Chang

Jiang

Pillarisetty

Role of immune cells in pancreatic cancer from bench to clinical application: An updated review

Medicine (Baltimore)95e55412016

10.1097/MD.0000000000005541

Kim

Lee

Autophagy--a key player in cellular and body metabolism

Nat Rev Endocrinol103223372014

10.1038/nrendo.2014.35

24663220

Tao

Yang

Zhang

Hai

Liu

Yuan

Autophagy suppresses self-renewal ability and tumorigenicity of glioma-initiating cells and promotes Notch1 degradation

Cell Death Dis910632018

10.1038/s41419-018-0957-3

30337536

6194143

Mowers

Sharifi

Macleod

Autophagy in cancer metastasis

Oncogene36161916302017

10.1038/onc.2016.333

5337449

Tan

Zhang

Zhou

Autophagy and its implication in human oral diseases

Autophagy132252362017

10.1080/15548627.2016.1234563

5324841

Green

Oguin

Martinez

The clearance of dying cells: Table for two

Cell Death Differ239159262016

10.1038/cdd.2015.172

26990661

4987729

Sionov

Vlahopoulos

Granot

Regulation of Bim in Health and Disease

Oncotarget623058231342015

10.18632/oncotarget.5492

26405162

4695108

Gafar

Draz

Goldberg

Bashandy

Bakry

Khalifa

AbuShair

Titorenko

Sanderson

Lithocholic acid induces endoplasmic reticulum stress, autophagy and mitochondrial dysfunction in human prostate cancer cells

PeerJ4e24452016

10.7717/peerj.2445

27896021

5119235

Jawhari

Ratinaud

Verdier

Glioblastoma, hypoxia and autophagy: A survival-prone ‘ménage-à-trois’

Cell Death Dis7e24342016

10.1038/cddis.2016.318

Mao

Zhang

Role of autophagy in chronic kidney diseases

Int J Clin Exp Med822022220292015

He Y

Luo

Qiao

Zuo

Deng

Nong

Peng

Induction of apoptosis and autophagy via mitochondria- and PI3K/Akt/mTOR-mediated pathways by E. adenophorum in hepatocytes of saanen goat

Oncotarget754537545482016

27391155

5342361

Goulielmaki

Koustas

Moysidou

Vlassi

Sasazuki

Shirasawa

Zografos

Oikonomou

Pintzas

BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells

Oncotarget7918892212016

10.18632/oncotarget.6942

26802026

4891035

Vera-Ramirez

Vodnala

Nini

Hunter

Green

Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence

Nat Commun919442018

10.1038/s41467-018-04070-6

29789598

5964069

Sun

Gao

Sun

Wogonin induces Beclin-1/PI3K and reactive oxygen species-mediated autophagy in human pancreatic cancer cells

Oncol Lett12505950672016

10.3892/ol.2016.5367

Klein

Werner

Teske

Schenk

Giese

Weitz

Welsch

Role of TFEB-driven autophagy regulation in pancreatic cancer treatment

Int J Oncol491641722016

10.3892/ijo.2016.3505

27175909

Kwon

Willy

Quirin

Wek

Korc

Yin

Kota

Novel role of miR-29a in pancreatic cancer autophagy and its therapeutic potential

Oncotarget771635716502016

10.18632/oncotarget.11928

27626694

5342107

Ranjan

Srivastava

Penfluridol suppresses pancreatic tumor growth by autophagy-mediated apoptosis

Sci Rep6261652016

10.1038/srep26165

27189859

4870635

Seo

Choi

Lee

Sung

Yoo

Kang

Cheong

Son

Autophagy is required for PDAC glutamine metabolism

Sci Rep6375942016

10.1038/srep37594

27892481

5124864

Yan

Jiang

Liu

Zhang

Dong

Gao

Liu

Barr

Zhang

Hou

Bafilomycin A1 induces caspase-independent cell death in hepatocellular carcinoma cells via targeting of autophagy and MAPK pathways

Sci Rep6370522016

10.1038/srep37052

27845389

5109251

Yang

Wang

Contino

Liesa

Sahin

Ying

Bause

Stommel

Dell’antonio

Pancreatic cancers require autophagy for tumor growth

Genes Dev257177292011

10.1101/gad.2016111

21406549

3070934

Yang

Herter-Sprie

Zhang

Lin

Biancur

Wang

Deng

Hai

Yang

Wong

Autophagy sustains pancreatic cancer growth through both cell autonomous and non-autonomous mechanisms

Cancer Discov82762872018

10.1158/2159-8290.CD-17-0952

29317452

5835190

Mukubou

Tsujimura

Sasaki

The role of autophagy in the treatment of pancreatic cancer with gemcitabine and ionizing radiation

Int J Oncol378218282010

20811703

Marinković

Šprung

Buljubašić

Novak

Autophagy Modulation in Cancer: Current Knowledge on Action and Therapy

Oxid Med Cell Longev201880238212018

Islam

Reesor

Zope

Zetter

Shi

Biomaterials for mRNA delivery

Biomater Sci3151915332015

10.1039/C5BM00198F

26280625

4641793

Liu

Gao

Yang

Zhao

Fan

Yang

Antitumor activity of curcumin by modulation of apoptosis and autophagy in human lung cancer A549 cells through inhibiting PI3K/Akt/mTOR pathway

Oncol Rep39152315312018

29328421

Chen

Xia

Yang

Huo

Tang

Yang

STAT3-induced lncRNA HAGLROS over-expression contributes to the malignant progression of gastric cancer cells via mTOR signal-mediated inhibition of autophagy

Mol Cancer1762018

10.1186/s12943-017-0756-y

Gong

Muñoz

Chan

Ghosh

Kumar

STAT3 down regulates LC3 to inhibit autophagy and pancreatic cancer cell growth

Oncotarget5252925412014

10.18632/oncotarget.1810

24796733

4058024

Raimondi

Cesselli

Di Loreto

La Marra

Schneider

Demarchi

USP1 (ubiquitin specific peptidase 1) targets ULK1 and regulates its cellular compartmentalization and autophagy

AutophagyOct182018Epub ahead of print

10.1080/15548627.2018.1535291

30335599

Pan

Chen

Zhang

Chu

Wang

Chen

The Emerging Roles of Long Noncoding RNA ROR (lincRNA-ROR) and its Possible Mechanisms in Human Cancers

Cell Physiol Biochem402192292016

10.1159/000452539

27855392

Bamodu

Huang

Lee

Wang

Hsiao

Yeh

Chao

Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448. BM

Cancer161602016

Zhang

Dang

Zhang

Wang

Huang

Jiang

Gan

Xie

Comprehensive analysis of the long noncoding RNA HOXA11-AS gene interaction regulatory network in NSCLC cells

Cancer Cell Int16892016

10.1186/s12935-016-0366-6

27980454

5133743

Peng

Yuan

The emerging landscape of circular RNA ciRS-7 in cancer (Review)

Oncol Rep33266926742015Review

10.3892/or.2015.3904

25873049

Deng

Yuan

Zhang

Yao

Wang

Liu

Identification of Circulating MiR-25 as a Potential Biomarker for Pancreatic Cancer Diagnosis

Cell Physiol Biochem39171617222016

10.1159/000447872

27639768

Zhang

LncRNA-LINC00152 down-regulated by miR-376c-3p restricts viability and promotes apoptosis of colorectal cancer cells

Am J Transl Res8528652972016

Yang

Wang

Gao

Shang

Sun

Dou

Circular RNA: A new star of noncoding RNAs

Cancer Lett3651411482015

10.1016/j.canlet.2015.06.003

26052092

Yang

Chen

The Biogenesis, Functions, and Challenges of Circular RNAs

Mol Cell714284422018

10.1016/j.molcel.2018.06.034

30057200

Xuan

Zhou

Wang

Tian

Liu

Circular RNA: A novel biomarker for progressive laryngeal cancer

Am J Transl Res89329392016

27158380

4846937

Jin

Feng

Xiang

Chen

CircRNA expression pattern and circRNA-miRNA-mRNA network in the pathogenesis of nonalcoholic steatohepatitis

Oncotarget766455664672016

10.18632/oncotarget.12186

27677588

5341813

Liu

Zhang

Dai

Zhang

Circular RNA Related to the Chondrocyte ECM Regulates MMP13 Expression by Functioning as a MiR-136 ‘Sponge’ in Human Cartilage Degradation

Sci Rep6225722016

10.1038/srep22572

Xie

Ren

Xin

Lan

Lin

Yang

Zeng

Liao

Ding

Emerging roles of circRNA_001569 targeting miR-145 in the proliferation and invasion of colorectal cancer

Oncotarget726680266912016

27058418

5042007

Zhong

Chen

Screening differential circular RNA expression profiles reveals the regulatory role of circTCF25-miR-103a-3p/miR-107-CDK6 pathway in bladder carcinoma

Sci Rep6309192016

10.1038/srep30919

27484176

4971518

Deng

Feng

Zheng

Lin

Gan

Fang

Zhang

Gao

PM2.5 exposure-induced autophagy is mediated by lncRNA loc146880 which also promotes the migration and invasion of lung cancer cells

Biochim Biophys Acta, Gen Subj18611121252017

Zhao

Zhou

Liu

Linc-ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR-124/PTBP1/PKM2 axis

Cancer Chemother Pharmacol78119912072016

10.1007/s00280-016-3178-4

27785603

Chen

Wang

Huang

Fang

Sun

Liu

Luo

Chen

The lncRNA HOTAIRM1 regulates the degradation of PML-RARA oncoprotein and myeloid cell differentiation by enhancing the autophagy pathway

Cell Death Differ242122242017

10.1038/cdd.2016.111

5299705

Pawar

Hanisch

Palma Vera

Einspanier

Sharbati

Down regulated lncRNA MEG3 eliminates mycobacteria in macrophages via autophagy

Sci Rep6194162016

10.1038/srep19416

26757825

4725832

Vega-Rubín-de-Celis

Zou

Fernández

Kim

Xiao

Xie

Levine

Increased autophagy blocks HER2-mediated breast tumorigenesis

Proc Natl Acad Sci USA115417641812018

10.1073/pnas.1717800115

29610308

5910832

Zarzynska

The importance of autophagy regulation in breast cancer development and treatment

BioMed Res Int20147103452014

Qin

Zheng

Guo

Zhang

Kang

Zhang

Yang

Inhibition of autophagy promotes metastasis and glycolysis by inducing ROS in gastric cancer cells

Oncotarget639839398542015

10.18632/oncotarget.5674

26497999

4741864

Cai

Zhang

Lian

Fang

Huang

Feng

Liu

CK1α suppresses lung tumour growth by stabilizing PTEN and inducing autophagy

Nat Cell Biol204654782018

10.1038/s41556-018-0065-8

29593330

Chen

Gombart

Chen

Chloroquine treatment of ARPE-19 cells leads to lysosome dilation and intracellular lipid accumulation: possible implications of lysosomal dysfunction in macular degeneration

Cell Biosci1102011

10.1186/2045-3701-1-10

21711726

3125200

Tan

Lin

Wang

Zhao

Chloroquine potentiates the anticancer effect of sunitinib on renal cell carcinoma by inhibiting autophagy and inducing apoptosis

Oncol Lett15283928462018

29435010

5778883

Maragkakis

Vergoulis

Alexiou

Reczko

Plomaritou

Gousis

Kourtis

Koziris

Dalamagas

Hatzigeorgiou

DIANA-microT Web server upgrade supports Fly and Worm miRNA target prediction and bibliographic miRNA to disease association

Nucleic Acids Res 39 (Web Server issue):W145W1482011

10.1093/nar/gkr294

Paraskevopoulou

Georgakilas

Kostoulas

Vlachos

Vergoulis

Reczko

Filippidis

Dalamagas

Hatzigeorgiou

DIANA-microT web server v5.0: Service integration into miRNA functional analysis workflows

Nucleic Acids Res41Web Server issueW169W1732013

10.1093/nar/gkt393

23680784

3692048

John

Enright

Aravin

Tuschl

Sander

Marks

Human MicroRNA targets

PLoS Biol2e3632004

10.1371/journal.pbio.0020363

15502875

521178

Tsang

Ebert

van Oudenaarden

Genome-wide dissection of microRNA functions and cotargeting networks using gene set signatures

Mol Cell381401532010

10.1016/j.molcel.2010.03.007

20385095

3110938

Wang

Improving microRNA target prediction by modeling with unambiguously identified microRNA-target pairs from CLIP-ligation studies

Bioinformatics32131613222016

10.1093/bioinformatics/btw002

26743510

6169475

Vejnar

Blum

Zdobnov

miRmap web: Comprehensive microRNA target prediction online

Nucleic Acids Res41Web Server issueW165W1682013

10.1093/nar/gkt430

23716633

3692044

Hsu

Chu

Tsou

Chen

Hsu

Wong

Chen

Huang

miRNAMap 2.0: Genomic maps of microRNAs in metazoan genomes

Nucleic Acids Res36DatabaseD165D1692008

10.1093/nar/gkm1012

2238982

Krek

Grün

Poy

Wolf

Rosenberg

Epstein

MacMenamin

da Piedade

Gunsalus

Stoffel

Combinatorial microRNA target predictions

Nat Genet374955002005

10.1038/ng1536

15806104

Kertesz

Iovino

Unnerstall

Gaul

Segal

The role of site accessibility in microRNA target recognition

Nat Genet39127812842007

10.1038/ng2135

17893677

Miranda

Huynh

Tay

Ang

Tam

Thomson

Lim

Rigoutsos

A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes

Cell126120312172006

10.1016/j.cell.2006.07.031

16990141

Rehmsmeier

Steffen

Hochsmann

Giegerich

Fast and effective prediction of microRNA/target duplexes

RNA10150715172004

10.1261/rna.5248604

15383676

1370637

Lewis

Burge

Bartel

Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets

Cell12015202005

10.1016/j.cell.2004.12.035

15652477

Michelson

Orkin

Characterization of the homo-polymer tailing reaction catalyzed by terminal deoxynucleotidyl transferase. Implications for the cloning of cDNA

J Biol Chem25714773147821982

6294077

Hoshino

Inagaki

A comparative study of microbial diversity and community structure in marine sediments using poly(A) tailing and reverse transcription-PCR

Front Microbiol41602013

10.3389/fmicb.2013.00160

23785366

3684792

Tajadini

Panjehpour

Javanmard

Comparison of SYBR Green and TaqMan methods in quantitative real-time polymerase chain reaction analysis of four adenosine receptor subtypes

Adv Biomed Res3852014

10.4103/2277-9175.127998

24761393

3988599

Mardis

McCombie

Library Quantification Using SYBR Green-Quantitative Polymerase Chain Reaction (qPCR)

Cold Spring Harb Protoc2017pdb prot0947142017

10.1101/pdb.prot094714

Livak

Schmittgen

Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method

Methods254024082001

10.1006/meth.2001.1262

Huang

Sherman

Lempicki

Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists

Nucleic Acids Res371132009

10.1093/nar/gkn923

2615629

Kang

Jang

Chang

Kwon

Jung

Kim

Revisiting the concept of lymph node metastases of pancreatic head cancer: Number of metastatic lymph nodes and lymph node ratio according to N stage

Ann Surg Oncol21154515512014

10.1245/s10434-013-3473-9

24419758

Georgiadou

Sergenta nis

T N

Sakellariou

Vlachodimitropoulos

Psaltopoulou

Lazaris

Gounaris

Zografos

Prognostic role of sex steroid receptors in pancreatic adenocarcinoma

Pathol Res Pract21238432016

10.1016/j.prp.2015.11.007

Lovecek

Skalicky

Klos

Bebarova

Neoral

Ehrmann

Zapletalova

Svebisova

Vrba

Stasek

Long-term survival after resections for pancreatic ductal adeno-carcinoma. Single centre study

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub1602802862016

10.5507/bp.2016.011

27029600

Ramacciato

Nigri

Petrucciani

Pinna

Ravaioli

Jovine

Minni

Grazi

Chirletti

Tisone

Pancreatectomy with Mesenteric and Portal Vein Resection for Borderline Resectable Pancreatic Cancer: Multicenter Study of 406 Patients

Ann Surg Oncol23202820372016

10.1245/s10434-016-5123-5

26893222

Chen

Xia

Jiang

Shao

Xiao

Guo

Non-coding RNAs and gastric cancer

World J Gastroenterol20541154192014

10.3748/wjg.v20.i18.5411

24833871

4017056

Kishikawa

Otsuka

Ohno

Yoshikawa

Takata

Koike

Circulating RNAs as new biomarkers for detecting pancreatic cancer

World J Gastroenterol21852785402015

10.3748/wjg.v21.i28.8527

26229396

4515835

Bolton

Tuzova

Walsh

Lynch

Perry

Noncoding RNAs in prostate cancer: the long and the short of it

Clin Cancer Res2035432014

10.1158/1078-0432.CCR-13-1989

Zhao

Song

Liu

The roles of ncRNAs and histone-modifiers in regulating breast cancer stem cells

Protein Cell789992016

10.1007/s13238-015-0199-4

4742390

Lan

Liu

Pei

Yang

Liu

Che

Xie

Landscape of RNAs in human lumbar disc degeneration

Oncotarget763166631762016

10.18632/oncotarget.11334

27542248

5325354

Jiang

Liu

Yan

Shi

A Feed-Forward Regulatory Loop between HuR and the Long Noncoding RNA HOTAIR Promotes Head and Neck Squamous Cell Carcinoma Progression and Metastasis

Cell Physiol Biochem40103910512016

10.1159/000453160

27941336

Dou

Cao

Yang

Ding

Hou

Luo

Kang

Yang

Jiang

Changing expression profiles of lncRNAs, mRNAs, circRNAs and miRNAs during osteoclastogenesis

Sci Rep6214992016

10.1038/srep21499

26856880

4746671

Huang

Zhong

Shu

Tian

Chen

Comprehensive analysis of differentially expressed profiles of lncRNAs and circRNAs with associated co-expression and ceRNA networks in bladder carcinoma

Oncotarget747186472002016

27363013

5216934

Zhou

Yin

Zhuang

Yue

Zhang

The Interaction Between MiR-141 and lncRNA-H19 in Regulating Cell Proliferation and Migration in Gastric Cancer

Cell Physiol Biochem36144014522015

10.1159/000430309

26160158

Zeng

Xiong

Pang

Zhang

Tang

Luo

Chen

Identification of molecular targets for esophageal carcinoma diagnosis using miRNA-seq and RNA-seq data from The Cancer Genome Atlas: A study of 187 cases

Oncotarget835681356992017

28415685

5482608

Massillo

Dalton

Farré

De Luca

De Siervi

Implications of microRNA dysregulation in the development of prostate cancer

Reproduction154R81R972017

10.1530/REP-17-0322

28878093

100

Murray

Bell

Raby

Rijlaarsdam

Gillis

Looijenga

Brown

Destenaves

Nicholson

Coleman

A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours

Br J Cancer1141511622016

10.1038/bjc.2015.429

4815809

101

Ouyang

Cui

MicroRNAs and cell cycle of malignant glioma

Int J Neurosci126192016

10.3109/00207454.2015.1017881

102

Del Vescovo

Denti

microRNA and Lung Cancer

Adv Exp Med Biol8891531772015

10.1007/978-3-319-23730-5_9

26659001

103

Rupaimoole

Slack

MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases

Nat Rev Drug Discov162032222017

10.1038/nrd.2016.246

28209991

104

Zhang

Tang

Chen

Ren

Liang

Dang

Rong

An Encapsulation of Gene Signatures for Hepatocellular Carcinoma, MicroRNA-132 Predicted Target Genes and the Corresponding Overlaps

PLoS One11e01594982016

10.1371/journal.pone.0159498

27467251

4965135

105

Lan

Zhang

Tang

Chen

MiR-133a is downregulated in non-small cell lung cancer: A study of clinical significance

Eur J Med Res20502015

10.1186/s40001-015-0139-z

25903369

4409717

106

Gan

Tang

Dang

Xie

Chen

Upregulated MiR-1269 in hepatocellular carcinoma and its clinical significance

Int J Clin Exp Med87147212015

25785048

4358503

107

Zhang

Rong

Hou

Xie

Chen

MicroRNA-141 is a biomarker for progression of squamous cell carcinoma and adenocarcinoma of the lung: Clinical analysis of 125 patients

Tohoku J Exp Med2351611692015

10.1620/tjem.235.161

25746592

108

Ren

Ding

Huang

Wang

Luo

Dang

Yang

Chen

Expression and clinicopathological significance of miR-193a-3p and its potential target astrocyte elevated gene-1 in non-small lung cancer tissues

Cancer Cell Int15802015

10.1186/s12935-015-0227-8

26257582

4528689

109

Liu

Ren

Luo

Rong

Chen

Dang

Down-Regulation of MiR-193a-3p Dictates Deterioration of HCC: A Clinical Real-Time qRT-PCR Study

Med Sci Monit21235223602015

10.12659/MSM.894077

26263159

4538786

110

Yang

He R

Lin

Chen

Lin

Wei

Liang

Luo

Gan

MiR-30a-5p suppresses cell growth and enhances apoptosis of hepatocellular carcinoma cells via targeting AEG-1

Int J Clin Exp Pathol815632156412015

111

Huang

Wang

Yang

Ren

Luo

Huang

Liang

Chen

Dang

Lower expressed miR-198 and its potential targets in hepatocellular carcinoma: A clinicopathological and in silico study

OncoTargets Ther9516351802016

10.2147/OTT.S108828

112

Zhang

Tang

Gan

Luo

Chen

Rong

Downregulation of microRNA-132 indicates progression in hepatocellular carcinoma

Exp Ther Med12209521012016

10.3892/etm.2016.3613

27698698

5038555

113

Frampton

Castellano

Colombo

Giovannetti

Krell

Jacob

Pellegrino

Roca-Alonso

Funel

Gall

MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression

Gastroenterology146268-277e182014

10.1053/j.gastro.2013.10.010

114

Frampton

Krell

Jamieson

Gall

Giovannetti

Funel

Mato Prado

Krell

Habib

Castellano

microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis

Eur J Cancer51138914042015

10.1016/j.ejca.2015.04.006

26002251

115

Giovannetti

Funel

Peters

Del Chiaro

Erozenci

Vasile

Leon

Pollina

Groen

Falcone

MicroRNA-21 in pancreatic cancer: Correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity

Cancer Res70452845382010

10.1158/0008-5472.CAN-09-4467

20460539

116

Ouyang

Gore

Deitz

Korc

microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-β actions

Oncogene33466446742014

10.1038/onc.2013.405

117

Nakata

Ohuchida

Mizumoto

Kayashima

Ikenaga

Sakai

Lin

Fujita

Otsuka

Aishima

MicroRNA-10b is overexpressed in pancreatic cancer, promotes its invasiveness, and correlates with a poor prognosis

Surgery1509169222011

10.1016/j.surg.2011.06.017

22018284

118

Zhang

Xiao

Wang

ceRNA in cancer: Possible functions and clinical implications

J Med Genet527107182015

10.1136/jmedgenet-2015-103334

26358722

119

Shao

Chen

Bai

Identification of module biomarkers from the dysregulated ceRNA-ceRNA interaction network in lung adenocarcinoma

Mol Biosyst11304830582015

10.1039/C5MB00364D

26325208

120

Pan

Ding

Wang

Shao

Zhang

Wang

The mRNA related ceRNA-ceRNA landscape and significance across 20 major cancer types

Nucleic Acids Res43816981822015

10.1093/nar/gkv853

26304537

4787795

121

Feng

Shao

Zhang

Qian

Xie

Wang

miR-124 downregulation leads to breast cancer progression via LncRNA-MALAT1 regulation and CDK4/E2F1 signal activation

Oncotarget716205162162016

26918449

4941308

122

Jin

Cao

Wang

Tan

Zou

Wang

miR-124 Inhibits Lung Tumorigenesis Induced by K-ras Mutation and NNK

Mol Ther Nucleic Acids91451542017

10.1016/j.omtn.2017.09.005

29246293

5633347

123

Wang

Meng

Liu

Chen

Liu

MiR-124 Inhibits Growth and Enhances Radiation-Induced Apoptosis in Non-Small Cell Lung Cancer by Inhibiting STAT3

Cell Physiol Biochem44201720282017

10.1159/000485907

29237164

124

Zhang

Gao

Zhou

Wang

Shi

Tan

UCA1 Regulates the Growth and Metastasis of Pancreatic Cancer by Sponging miR-135a

Oncol Res25152915412017

10.3727/096504017X14888987683152

28315290

125

Wang

Zhang

Chen

Meng

MicroRNA targets autophagy in pancreatic cancer cells during cancer therapy

Autophagy9217121722013

10.4161/auto.26463

24145177

126

Ganley

Lam

Wang

Ding

Chen

Jiang

ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy

J Biol Chem28412297123052009

10.1074/jbc.M900573200

19258318

2673298

127

Hosokawa

Hara

Kaizuka

Kishi

Takamura

Miura

Iemura

Natsume

Takehana

Yamada

Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy

Mol Biol Cell20198119912009

10.1091/mbc.e08-12-1248

19211835

2663915

128

Jung

Jun

Kim

Otto

Cao

Kundu

Kim

ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery

Mol Biol Cell20199220032009

10.1091/mbc.e08-12-1249

19225151

2663920

129

Yan

Kuroyanagi

Tomemori

Okazaki

Asato

Matsuda

Suzuki

Ohshima

Mitani

Masuho

Mouse ULK2, a novel member of the UNC-51-like protein kinases: Unique features of functional domains

Oncogene18585058591999

10.1038/sj.onc.1202988

10557072

130

Chan

Longatti

McKnight

Tooze

Kinase-inactivated ULK proteins inhibit autophagy via their conserved C-terminal domains using an Atg13-independent mechanism

Mol Cell Biol291571712009

10.1128/MCB.01082-08

2612494

131

Kundu

Lindsten

Yang

Zhao

Zhang

Selak

Ney

Thompson

Ulk1 plays a critical role in the autophagic clearance of mitochondria and ribosomes during reticulocyte maturation

Blood112149315022008

10.1182/blood-2008-02-137398

18539900

2515143

132

Zhang

Yang

MicroRNA-195 regulates proliferation, migration, angiogenesis and autophagy of endothelial progenitor cells by targeting GABARAPL1

Biosci Rep36362016

10.1042/BSR20160139

133

Zang

Wang

Chen

Zhao

miR-663 attenuates tumor growth and invasiveness by targeting eEF1A2 in pancreatic cancer

Mol Cancer14372015

10.1186/s12943-015-0315-3

25744894

4332743

134

Huang

Guo

Zhao

Yuan

miR-663a inhibits hepatocellular carcinoma cell proliferation and invasion by targeting HMGA2

Biomed Pharmacother814314382016

10.1016/j.biopha.2016.04.034

27261623

135

Zhang

Wang

Bai

Kan

Zhou

Niu

MicroRNA-663a is downregulated in non-small cell lung cancer and inhibits proliferation and invasion by targeting JunD

BMC Cancer163152016

10.1186/s12885-016-2350-x

27184257

4869303

136

Kuroda

Fukuda

Krstic-Demonacos

Demonacos

Okumura

Isogai

Hayashi

Saito

Isogai

miR-663a regulates growth of colon cancer cells, after administration of antimicrobial peptides, by targeting CXCR4-p21 pathway

BMC Cancer17332017

10.1186/s12885-016-3003-9

28061765

5219750

137

Lin

Kuang

Xie

Liu

IL-12 induces autophagy in human breast cancer cells through AMPK and the PI3K/Akt pathway

Mol Med Rep16411341182017

10.3892/mmr.2017.7114

28765958

138

Zhang

Feng

Liu

Wang

Quercetin prevents hepatic fibrosis by inhibiting hepatic stellate cell activation and reducing autophagy via the TGF-β1/Smads and PI3K/Akt pathways

Sci Rep792892017

10.1038/s41598-017-09673-5

139

Ren

Han

Yang

Sun

Zhang

Hua

Peng

Autophagy stimulated proliferation of porcine PSCs might be regulated by the canonical Wnt signaling pathway

Biochem Biophys Res Commun4795375432016

10.1016/j.bbrc.2016.09.105

27664705

140

Lin

Feng

Dong

Pan

Zhuang

Ding

Regulation of autophagy of prostate cancer cells by β-catenin signaling

Cell Physiol Biochem359269322015

10.1159/000369749

141

Zhao

Wang

Xiao

Lin

Cong

Cheng

Yang

Sun

H2O2 treatment or serum deprivation induces autophagy and apoptosis in naked mole-rat skin fibroblasts by inhibiting the PI3K/Akt signaling pathway

Oncotarget784839848502016

10.18632/oncotarget.13321

27863375

5356702

142

Wang

Neuroprotective effect of miR-665 against sevoflurane anesthesia-induced cognitive dysfunction in rats through PI3K/Akt signaling pathway by targeting insulin-like growth factor 2

Am J Transl Res9134413562017

28386360

5376025

143

Wang

Role of Wnt/β-catenin pathway in inducing autophagy and apoptosis in multiple myeloma cells

Oncol Lett12462346292016

10.3892/ol.2016.5289

144

Kai

Qiang

Xinxin

Miaomiao

Kuailu

Decreased miR-154 expression and its clinical significance in human colorectal cancer

World J Surg Oncol131952015

10.1186/s12957-015-0607-5

26048406

4472271

145

Fei

Zong

Fan

MicroRNA-154 inhibits growth and invasion of breast cancer cells through targeting E2F5

Am J Transl Res8262026302016

27398145

4931156

146

Liu

Zhao

Insulin-like growth factor 1 antagonizes lumbar disc degeneration through enhanced autophagy

Am J Transl Res8434643532016

27830018

5095327

147

Liu

Guan

Sun

Zhang

Liu

Insulin-like growth factor 1 receptor-mediated cell survival in hypoxia depends on the promotion of autophagy via suppression of the PI3K/Akt/mTOR signaling pathway

Mol Med Rep15213621422017

10.3892/mmr.2017.6265

28260056

5364871

148

Ceperuelo-Mallafré

Ejarque

Serena

Duran

Montori-Grau

Rodríguez

Yanes

Núñez-Roa

Roche

Puthanveetil

Adipose tissue glycogen accumulation is associated with obesity-linked inflammation in humans

Mol Metab55182015

10.1016/j.molmet.2015.10.001

149

Ciarcia

Damiano

Montagnaro

Pagnini

Ruocco

Caparrotti

d’ Angelo

Boffo

Morales

Rizzolio

Combined effects of PI3K and SRC kinase inhibitors with imatinib on intracellular calcium levels, autophagy, and apoptosis in CML-PBL cells

Cell Cycle12283928482013

10.4161/cc.25920

23966159

3899197

150

Hua

Han

Zhang

Dai

Liu

cPKCγ-Modulated Sequential Reactivation of mTOR Inhibited Autophagic Flux in Neurons Exposed to Oxygen Glucose Deprivation/Reperfusion

Int J Mol Sci19192018

10.3390/ijms19051380

151

Shivaram

Crist

Chaudhuri

Mucci

Chaudhuri

Effect of CCK receptor antagonist on growth of pancreatic adenocarcinoma

J Surg Res532342371992

10.1016/0022-4804(92)90040-7

1528048

152

Clerc

Saillan-Barreau

Desbois

Pradayrol

Fourmy

Dufresne

Transgenic mice expressing cholecystokinin 2 receptors in the pancreas

Pharmacol Toxicol913213262002

10.1034/j.1600-0773.2002.910609.x

153

Shang

Zhu

Liu

Wang

Huang

Zhao

Yao

Characterization of long non-coding RNA expression profiles in lymph node metastasis of early-stage cervical cancer

Oncol Rep35318531972016

10.3892/or.2016.4715

27035672

4869942

154

Bronietzki

Schuster

Schmitz

Autophagy in T-cell development, activation and differentiation

Immunol Cell Biol9325342015

10.1038/icb.2014.81

155

Martinez-Lopez

Athonvarangkul

Singh

Autophagy and aging

Adv Exp Med Biol84773872015

10.1007/978-1-4939-2404-2_3

25916586

4644734

156

Tan

Gong

Dong

Pei

Ren

Role of autophagy in inherited metabolic and endocrine myopathies

Biochim Biophys Acta Mol Basis Dis186548552018

157

Chu

Autophagy in Neurological Diseases: An update

Neurobiol DisS0969–9961183072892018

158

Yang

Rajeshkumar

Wang

Yabuuchi

Alexander

Chu

Von Hoff

Maitra

Kimmelman

Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations

Cancer Discov49059132014

10.1158/2159-8290.CD-14-0362

24875860

4125497

159

Zhan

Wang

Zou

Chen

Gong

Yin

Zhang

The Novel Autophagy Inhibitor Alpha-Hederin Promoted Paclitaxel Cytotoxicity by Increasing Reactive Oxygen Species Accumulation in Non-Small Cell Lung Cancer Cells

Int J Mol Sci19192018

10.3390/ijms19103221

160

Chen

Jiao

Chen

Kang

Zhao

Shi

Fan

MicroRNA-495-3p inhibits multidrug resistance by modulating autophagy through GRP78/mTOR axis in gastric cancer

Cell Death Dis910702018

10.1038/s41419-018-0950-x

30341283

6195618

161

Verma

Das

Monensin induces cell death by autophagy and inhibits matrix metalloproteinase 7 (MMP7) in UOK146 renal cell carcinoma cell line

In Vitro Cell Dev Biol Anim547367422018

10.1007/s11626-018-0298-7

30324243

Figure 1

The design of the present study.

Figure 2

Autophagy inhibition caused by chloroquine diphosphate in PANC-1 cells. (A) Western blot analysis was used to detect the expression of LC3-II and P62 protein in PANC-1 cells treated with different concentrations of chloroquine diphosphate to detect the level of autophagy (^*P<0.05 vs. 0 µM). (B) When the concentration of chloroquine diphosphate was 100 µM, the difference of LC3-II and P62 protein was statistically significant, compared with the control group. LC3, microtubule-associated protein-1-light-chain-3.

Figure 3

Scatterplots of the differentially-expressed mRNAs following autophagy being inhibited. Differentially-expressed mRNAs were screened with a microarray following autophagy being inhibited with chloroquine diphosphate at a concentration of 100 µM.

Figure 4

Scatterplots of the differentially-expressed lncRNAs following autophagy being inhibited. Differentially-expressed lncRNAs were screened with a microarray following autophagy being inhibited with chloroquine diphosphate at a concentration of 100 µM. lncRNA, long non-coding RNA.

Figure 5

Scatterplots of the differentially-expressed circRNAs following autophagy being inhibited. Differentially-expressed circRNAs were screened with a microarray following autophagy being inhibited with chloroquine diphosphate at a concentration of 100 µM. circRNA, circular RNA.

Figure 6

Expression level, stage and overall survival curves of ATG12, GABARAPL1 and ULK2 in patients with pancreatic cancer. (A) The fold change of ATG12 (fold change=2.34), GABARAPL1 (fold change=3.90) and ULK2 (fold change=2.29) in the chloroquine diphosphate treatment group, compared with the control group. (B) The expression of ATG12 was upregulated in pancreatic cancer tissues, compared with normal tissues [T, n=179; N, n=171]. (C) ATG12 expression in different stages of pancreatic cancer is not significantly different (P=0.6140). (D) Patients with pancreatic cancer and a low expression of ATG12 have an increased survival time, compared with those with a high expression of ATG12 (HR=1.8; P=0.0042). (E) GABARAPL1 has an increased expression in pancreatic cancer tissues, compared with normal tissues [T, n=179; N, n=171]. (F) The association between GABARAPL1 and stage of patients with pancreatic cancer (P=0.5940). (G) The effect of GABARAPL1 expression on the overall survival time of patients with pancreatic cancer is not significant (HR=0.72; P=0.1100). (H) ULK2 has an increased expression in pancreatic cancer tissues, compared with normal tissues [T, n=179; N, n=171]. (I) The association between ULK2 and stage of patients with pancreatic cancer (P=0.0248). (J) The effect of ULK2 expression on the overall survival time of patients with pancreatic cancer is not significant (HR=0.79; P=0.2500). ATG12, autophagy-related 12; GABARAPL1, GABA type A receptor associated protein like 1; ULK2, Unc-51 like autophagy activating kinase 2; HR, hazard ratio; TPM, transcript per million.

Figure 7

Potential target genes of microRNA-663a-5p associated with autophagy. The 462 genes from target prediction and differentially-expressed mRNAs were depicted in Compendia expression profiles.

Figure 8

Circular visualization of the results of GO and KEGG pathway analysis of miR-663a-5p target genes. (A) The horizontal axis depicts the number of downregulated genes of miR-663a-5p. The vertical axis depicts the GO categories. (B) Circle plot demonstrating the significance of the pathway enriched by the target genes of miR-663a-5p. Inner plot color corresponds to the z-score. The outer ring displays scatterplots of the expression levels (logFC) for the genes in each term. (C) Cluster plot depicting a circular dendrogram of the target genes of miR-663a-5p. The inner ring depicts the color-coded logFC, the outer ring depicts the assigned functional terms. (D) Chord plot depicting the target genes of miR-663a-5p associations via ribbons to their assigned pathways. Colored rectangles represent the logFC of genes. GO, Gene Ontology; miR, microRNA; logFC, log fold change; PI3K, phosphoinositide 3-kinase.

Figure 9

Potential target genes of microRNA-154-3p associated with autophagy. The 294 genes from target prediction and differentially-expressed mRNAs were depicted in Compendia expression profiles.

Figure 10

Circular visualization of the results of GO and KEGG pathway analysis of miR-154-3p target genes. (A) The horizontal axis depicts the number of downregulated genes of miR-154-3p. The vertical axis depicts the GO categories. (B) Circle plot depicting the significance of the pathway enriched by the target genes of mir-154-3p. Inner plot color corresponds to the z-score. The outer ring displaying scatterplots of the expression levels (logFC) for the genes in each term. (C) Cluster plot displaying a circular dendrogram of the target genes of mir-154-3p. The inner ring depicting the color-coded logFC, the outer ring depicting the assigned functional terms. (D) Chord plot depicting the target genes of miR-154-3p associations via ribbons to their assigned pathways. Colored rectangles represent the logFC of genes. miR, microRNA; logFC, log fold change; FoxO, Forkhead box O; MAPK, mitogen-activated protein kinase.

Figure 11

Bubble Chart of the results of PANTHER analyses. (A) Pathway visualization of the targeted genes of miR-154-3p. (B) Pathway visualization of the targeted genes of miR-154-3p. miR, microRNA; CCKR, classical gastrin cholecystokinin receptor; MAPK, mitogen-activated protein kinase; MAP2K, mitogen-activated protein kinase kinase; EGF, epidermal growth factor; PI3K, phosphoinositide 3-kinase.

Figure 12

ceRNA network of miR-663a-5p. The predicted ceRNA of miR-663a-5p included 9 upregulated circRNAs, 8 upregulated lncRNAs, miR-663a-5p and 46 differentially-expressed mRNA, which were differentially expressed in the ceRNA microarray results as well. Nodes in green, yellow, red and blue represent circRNAs, lncRNAs, miRNA-663a-5p and mRNAs, respectively. miR, microRNA; circRNA, circular RNA; lncRNA, long non-coding RNA; ceRNA, competitive endogenous RNA.

Figure 13

ceRNA network of miR-154-3p. The predicted ceRNA of miR-154-3p included 5 upregulated circRNAs, 2 upregulated lncRNAs, miR-154-3p and 11 differentially-expressed mRNA, which were differentially expressed in the ceRNA microarray results as well. Nodes in yellow, green, red and blue represent circRNAs, lncRNAs, miRNA-154-3p and mRNAs, respectively. The arrows indicate the direction of transcription. miR, microRNA; circRNA, circular RNA; lncRNA, long non-coding RNA; ceRNA, competitive endogenous RNA.

Figure 14

Meta-analysis of miR-663a-5p in pancreatic cancer. (A) A forest plot of miR-663a-5p expression. (B) Sensitivity analysis for miR-663a-5p and (C) Begg’s funnel plot of miR-663a-5p expression (Pr>|z|=0.548). miR, microRNA; SMD, standardized mean difference; s.e., standard error of the effect size.

Figure 15

Meta-analysis of miR-154-3p in pancreatic cancer. (A) A forest plot of miR-154-3p expression. (B) Sensitivity analysis for miR-154-3p. (C) Begg’s funnel plot of miR-154-3p expression (Pr>|z|=0.707). miR, microRNA; SMD, standardized mean difference; s.e., standard error of the effect size.

Table I

GO analysis of differentially-expressed mRNAs following autophagy inhibition.

GO ID	Description	Type	Genes
GO:2000969	Positive regulation of α-amino-3-hydroxy-5-methyl-4-isoxazole propionate selective glutamate receptor activity	Biological_process	RELN, NLGN3, ARC and SHANK3
GO:0000727	Double-strand break repair via break-induced replication	Biological_process	CDC45, GINS2, CDC7 and GINS4
GO:0038026	Reelin-mediated signaling pathway	Biological_process	DAB2IP, RELN, LRP8 and VLDLR
GO:0003150	Muscular septum morphogenesis	Biological_process	HEY2, FZD2, VANGL2 and FZD1
GO:0050915	Sensory perception of sour taste	Biological_process	ASIC3, PKD2L1, ASIC2, PKD1L3 and ASIC1
GO:0031052	Chromosome breakage	Biological_process	HMGA2, BRCA2, BRCA1, CD19 and TP53
GO:0038171	Cannabinoid signaling pathway	Biological_process	DAGLA, CNR2, MGLL, ABHD6 and CNR1
GO:0003149	Membranous septum morphogenesis	Biological_process	ID2, WHSC1, FZD2, VANGL2 and FZD1
GO:0061156	Pulmonary artery morphogenesis	Biological_process	HEY2, STRA6, BMP4 and JAG1
GO:2001286	Regulation of caveolin-mediated endocytosis	Biological_process	UNC119, NEDD4L, CAV3 and PROM2
GO:0000942	Condensed nuclear chromosome outer kinetochore	Cellular_component	PLK1, BUB1, CCNB1 and NDC80
GO:0031262	Ndc80 complex	Cellular_component	SPC24, NUF2, SPC25 and NDC80
GO:0031298	Replication fork protection complex	Cellular_component	CDC45, MCM10, GINS2, TOP1MT and GINS4
GO:0072557	IPAF inflammasome complex	Cellular_component	CASP1, CASP12, CASP5 and NLRC4
GO:0000778	Condensed nuclear chromosome kinetochore	Cellular_component	PLK1, CENPA, NDC80, BUB1B, BUB1, CCNB1 and MIS18BP1
GO:0042555	MCM complex	Cellular_component	MCM4, TONSL, MCM5, MMS22L, MCM8, MCM2, MCMBP and MCM3
GO:0000940	Condensed chromosome outer kinetochore	Cellular_component	PLK1, SKA3, CENPF, NDC80, BUB1, BUB1B, CENPE, CCNB1 and SPDL1
GO:0005663	DNA replication factor c complex	Cellular_component	RFC4, PCNA, RFC3 and RFC5
GO:0097169	AIM2 inflammasome complex	Cellular_component	CASP1, CASP12, CASP5 and PYCARD
GO:0043240	Fanconi anemia nuclear complex	Cellular_component	FANCB, FANCC, C19ORF40, STRA13, FANCG, FANCM, FANCA and FANCE
GO:0043142	Single-stranded DNA-dependent ATPase activity	Molecular_function	PIF1, RAD18, RAD51, DNA2 and POLQ
GO:0032405	Mutlalpha complex binding	Molecular_function	TREX1, PCNA, MUTYH, MSH6 and MSH2
GO:0086006	Voltage-gated sodium channel activity involved in cardiac muscle cell action potential	Molecular_function	SCN1B, SCN4B, SCN3B and SCN2B
GO:0008574	Plus-end-directed microtubule motor activity	Molecular_function	KIF3B, KIF18B, KIF5A, KIF14, KIF5C, KIF3A, KIF20B, KIF17, KIF11, KIF26A and KIF16B
GO:0004908	Interleukin-1 receptor activity	Molecular_function	IL1R1, IL1RL2, IL1RL1, IL18R1 and IL1R2
GO:0032027	Myosin light chain binding	Molecular_function	CXCR4, IQGAP3, MYOC and MYH8
GO:0035312	5′-3′ exodeoxyribonuclease activity	Molecular_function	EXO1, DCLRE1B, EXO5 and DCLRE1A
GO:0048256	Flap endonuclease activity	Molecular_function	EXO1, MUS81, FEN1, DNA2 and FAN1
GO:0036310	Annealing helicase activity	Molecular_function	RECQL4, SMARCA1, SMARCAL1, RAD54L and BLM
GO:0097153	Cysteine-type endopeptidase activity involved in apoptotic process	Molecular_function	CASP7, CASP6, CASP12, PYCARD, CASP2, CASP8, CLC, CASP1 and CASP5

Only the top 10 signaling pathways of each classification were listed as examples. GO, Gene Ontology.

Table II

Kyoto Encyclopedia of Genes and Genomes pathway analysis of differentially-expressed mRNAs when autophagy was inhibited.

Pathway ID	Description	Genes
hsa05200	Pathways in cancer	BCR, PDGFB, WNT4, ETS1, CASP8, BRCA2, ARHGEF11, TRAF3, GNAI3 and BID
hsa04060	Cytokine-cytokine receptor interaction	CCL4, PDGFB, IL4R, CCL21, IL12A, CSF2, GH2, CCL27, ACVR1B and LEP
hsa04010	MAPK signaling pathway	PDGFB, MAP2K6, CACNG8, RPS6KA2, PLA2G4A, MAP3K4, GADD45G, CACNB3, JUN and TNFRSF1A
hsa04144	Endocytosis	FOLR3, NEDD4L, PSD4, SH3KBP1, GRK5, ERBB4, EHD2, CAV2, ITCH and EPS15L1
hsa04080	Neuroactive ligand- receptor interaction	ADRA1D, GH2, PTAFR, C5AR1, GRIN3B, HTR1B, LEP, S1PR5, LPAR2, CHRND, AGTR1, GH1, CHRM1, SSTR5, ADRA1B, GRIN3A, DRD5 and PTGER3
hsa04621	NOD-like receptor signaling pathway	CASP8, ATG12, TRAF3, TRAF5, JUN, OAS3, OAS1, MAVS, RNASEL and NLRP7
hsa00230	Purine metabolism	PFAS, PDE6G, POLD3, NME7, PDE9A, POLR3H, POLR2L, ADCY7, NME6 and NPR2
hsa04110	Cell cycle	RAD21, CDC16, E2F2, SFN, GADD45G, CCNH, CDC20, CDC25A, CCNA1 and TP53
hsa04062	Chemokine signaling pathway	CCL4, CCL21, GNAI3, PIK3R5, GRK5, CCL27, PIK3CB, SHC1, VAV1 and CCL4L1
hsa04210	Apoptosis	CASP8, BID, PIK3R5, CTSC, LMNB1, PIK3CB, EIF2AK3, GADD45G, CASP6 and TRADD

Only 10 genes were listed as examples in each pathway. MAPK, mitogen-activated protein kinase.

Table III

GO and KEGG analysis of potential target genes of microRNA-663a-5p related to autophagy.

Term	Description	Type	Count	P-value	Genes
GO:0048562	Embryonic organ morphogenesis	Biological process	11	1.66×10⁻³	DLX2, FOXL2, TBX15, MAFB, CHST11, NKX3-2, SOBP, TBX1, ZEB1 and PAX2
GO:0045449	Regulation of transcription	Biological process	87	1.71×10⁻³	ZNF451, NR6A1, ZNF250, CBX2, ZEB1, MED22, PAX2, CBFA2T3, ZNF345 and TGFB1
GO:0006350	Transcription	Biological process	73	1.78×10⁻³	NR6A1, ZNF451, ZNF250, CBX2, MED22, ZEB1, PAX2, CBFA2T3, ZNF345 and CRX
GO:0043583	Ear development	Biological process	9	2.35×10⁻³	KCNMA1, MAFB, NKX3-2, SOBP, TBX1, PAX2, SLC9A3R2, TGFB1 and CDH23
GO:0017015	Regulation of transforming growth factor β receptor signaling pathway	Biological process	6	2.54×10⁻³	DAND5, CHST11, TGFB1I1, ZEB1, PRDM16 and TGFB1
GO:0048839	Inner ear development	Biological process	8	3.27×10⁻³	KCNMA1, MAFB, SOBP, TBX1, PAX2, SLC9A3R2, TGFB1 and CDH23
GO:0048568	Embryonic organ development	Biological process	12	3.56×10⁻³	DLX2, FOXL2, TBX15, MAFB, FOXF1, CHST11, NKX3-2, SOBP, TBX1 and ZEB1
GO:0006357	Regulation of transcription from RNA polymerase II promoter	Biological process	31	3.82×10⁻³	TADA3, CRTC1, NR6A1, CBX2, ZEB1, MED22, PAX2, PRDM16, ZNF345 and TGFB1
GO:0006355	Regulation of transcription DNA-dependent	Biological process	62	3.88×10⁻³	NR6A1, ZNF250, CBX2, MED22, ZEB1, CBFA2T3, PAX2, ZNF345, TGFB1 and CRX
GO:0048598	Embryonic morphogenesis	Biological process	17	3.96×10⁻³	FOXL2, TBX15, MAFB, ARFRP1, TP53, SOBP, TBX1, ZEB1, CELSR1 and PAX2
GO:0030054	Cell junction	Cellular component	27	1.02×10⁻⁴	ACHE, CLDN9, PANX2, CLDN6, GRIK5, ZNRF1, ITSN1, SYNGR1, CALB2 and RIMS3
GO:0045202	Synapse	Cellular component	21	1.45×10⁻⁴	KCNMA1, DLGAP1, ACHE, CDK5R1, ARC, EFNA2, SYT11, GRIK5, BCAN and BSN
GO:0044459	Plasma membrane part	Cellular component	68	4.22×10⁻³	KCNC1, PCDHA8, CLDN9, CD8A, CLDN6, GRIK5, ANPEP, SYNGR1, ITSN1 and ZNRF1
GO:0019717	Synaptosome	Cellular component	7	1.19×10⁻²	PVRL1, SNPH, DLG4, BSN, LGI3, ITSN1 and RNF40
GO:0030173	Integral to golgi membrane	Cellular component	5	1.53×10⁻²	ST6GAL1, ST8SIA4, RER1, STEAP2 and ABO
GO:0031228	Intrinsic to golgi membrane	Cellular component	5	1.92×10⁻²	ST6GAL1, ST8SIA4, RER1, STEAP2 and ABO
GO:0005794	Golgi apparatus	Cellular component	29	3.41×10⁻²	SLC9A8, ACHE, APC2, C6ORF25, PPIL2, ARFRP1, RER1, VPS53, CBFA2T3 and NUFIP2
GO:0005886	Plasma membrane	Cellular component	99	4.57×10⁻²	KCNC1, ALPPL2, PLXNA1, ATP1B2, C6ORF25, EFNA2, FGFRL1, GRIK5, ZNRF1, TLR6 and ITSN1
GO:0031012	Extracellular matrix	Cellular component	14	4.66×10⁻²	ACHE, ADAMTS14, ADAMTSL2, ADAMTS15, OLFML2A, BCAN, COL5A1, MMP25, TGFB1 and WNT7B
GO:0005667	Transcription factor complex	Cellular component	10	4.72×10⁻²	BRF1, TADA3, TBX2, MAFB, FOXF1, NR6A1, TP53, NPAS4, ZEB1 and CRX
GO:0046872	Metal ion binding	Molecular function	123	1.21×10⁻²	KCNC1, SLC9A8, ALAD, FSTL4, ALPPL2, ATP1B2, ZNF451, ZNF250, RNF216 and ITSN1
GO:0008270	Zinc ion binding	Molecular function	74	1.44×10⁻²	ALPPL2, ALAD, ZCCHC24, ZNF451, NR6A1, SOBP, ZNF250, ANPEP, RNF216 and ZEB1
GO:0043169	Cation binding	Molecular function	123	1.64×10⁻²	KCNC1, SLC9A8, ALAD, ALPPL2, ATP1B2, ZNF451, FSTL4, ZNF250, RNF216 and ITSN1
GO:0019209	Kinase activator activity	Molecular function	4	2.32×10⁻²	CDK5R1, MADD, ITSN1 and TAB1
GO:0043167	Ion binding	Molecular function	123	2.58×10⁻²	KCNC1, SLC9A8, ALAD, ALPPL2, ATP1B2, ZNF451, FSTL4, ZNF250, RNF216 and ITSN1
GO:0003677	DNA binding	Molecular function	72	3.34×10⁻²	PRR12, NR6A1, ZNF451, ZNF250, CBX2, ZEB1, PAX2, CBFA2T3, ZNF345 and CRX
GO:0046914	Transition metal ion binding	Molecular function	84	3.45×10⁻²	STEAP3, ALPPL2, ALAD, ZCCHC24, ZNF451, NR6A1, SOBP, ZNF250, ANPEP and RNF216
GO:0030955	Potassium ion binding	Molecular function	8	4.02×10⁻²	KCNMA1, KCNC1, SLC12A7, PDXK, ATP1B2, KCNK5, HCN4 and KCNG1
GO:0030528	Transcription regulator activity	Molecular function	49	4.27×10⁻²	NR6A1, CBX2, ZEB1, MED22, CBFA2T3, ZNF345, TGFB1, CRX, FOXF1 and ZNF445
GO:0016419	S-malonyltransferase activity	Molecular function	2	4.90×10⁻²	MCAT and FASN
hsa04960	Aldosterone-regulated sodium reabsorption	KEGG pathway	5	9.51×10⁻³	ATP1B2, PIK3R5, NEDD4L, SFN and SLC9A3R2
hsa04310	Wnt signaling pathway	KEGG pathway	8	2.92×10⁻²	WNT7B, SOST, VANGL1, APC2, TP53, FZD1, FRAT1 and FZD4
hsa05217	Basal cell carcinoma	KEGG pathway	5	3.03×10⁻²	WNT7B, APC2, TP53, FZD1 and FZD4
hsa00061	Fatty acid biosynthesis	KEGG pathway	3	3.08×10⁻²	MCAT, FASN and ACSL6
hsa04151	PI3K-Akt signaling pathway	KEGG pathway	14	3.48×10⁻²	FGF18, IL2RB, LAMB3, FLT1, IL4R, CSF1, EFNA2, TP53, TNN and EFNA5
hsa05205	Proteoglycans in cancer	KEGG pathway	9	6.69E×10⁻²	WNT7B, CTTN, EZR, ANK1, TP53, FZD1, PIK3R5, FZD4 and TGFB1
hsa04724	Glutamatergic synapse	KEGG pathway	6	9.94×10⁻²	DLGAP1, SLC1A7, DLG4, GRIK5, CACNA1D and SHANK3

Only 10 genes were listed as examples in each pathway. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; PI3K, phosphoinositide 3-kinase.

Table IV

GO and KEGG analysis of potential target genes of microRNA-154-3p associated with autophagy.

Term	Description	Type	Count	P value	Genes
GO:0007605	Sensory perception of sound	Biological process	11	1.67×10⁻³	NAV2, ASIC2, DCDC2, SOBP, TBX1, TIMM13, CACNA1D, FZD4, SLC52A3 and DNM1
GO:0030512	Negative regulation of transforming growth factor β receptor signaling pathway	Biological process	7	4.81×10⁻³	DAND5, ADAMTSL2, ZNF451, CHST11, TGFB1I1, PRDM16 and TGFB1
GO:0072207	Metanephric epithelium development	Biological process	3	5.74×10⁻³	WNT7B, OSR1 and PAX2
GO:0070507	Regulation of microtubule cytoskeleton organization	Biological process	4	6.52×10⁻³	DIXDC1, CDK5R1, ATAT1 and EFNA5
GO:0045216	Cell-cell junction organization	Biological process	4	9.16×10⁻³	CLDN9, CLDN6, MARVELD3 and TGFB1
GO:0008285	Negative regulation of cell proliferation	Biological process	19	9.45×10⁻³	TP53I11, NACC2, CLMN, KLF10, FGFRL1, TP53, GPER1, ZEB1, CBFA2T3 and TGFB1
GO:0031497	Chromatin assembly	Biological process	3	1.53×10⁻²	CDAN1, TP53 and CHAF1A
GO:0006366	Transcription from RNA polymerase II promoter	Biological process	22	1.62×10⁻²	MAF, MAFF, FOXL2, POLR2L, MAFB, SOX12, TP53, ARID3B, FOSB and NPAS4
GO:0008104	Protein localization	Biological process	6	1.69×10⁻²	TNS4, MALL, CDAN1, TP53, GRASP and AKAP3
GO:0000122	Negative regulation of transcription from RNA polymerase II promoter	Biological process	28	1.98×10⁻²	NR6A1, CBX2, ZEB1, PRDM16, ZNF345, TGFB1, KANK2, AHRR, EZR and OSR1
GO:0030054	Cell junction	Cellular component	24	6.45×10⁻⁴	SH3PXD2B, ARC, DLGAP1, ACHE, SH3PXD2A, CACNG8, SYT11, GRIK5, LRRC4B and BSN
GO:0014069	Postsynaptic density	Cellular component	13	1.51×10⁻³	DLGAP1, ARC, CDK5R1, CACNG8, SYT11, GRIK5, BSN, GPER1, SHANK3 and CNIH2
GO:0005737	Cytoplasm	Cellular component	152	2.33×10⁻³	RBPMS2, STIL, PLXNA1, ATP1B2, LRRC4B, MED22, CALB2, TGFB1, KANK2 and PACSIN1
GO:0043197	Dendritic spine	Cellular component	9	2.60×10⁻³	CDK5R1, ARC, CTTN, CNIH2, SYT11, DLG4, ASIC2, SEZ6 and SHANK3
GO:0044297	Cell body	Cellular component	7	3.72×10⁻³	GNAZ, EZR, SYT11, PACRG, FADD, DISC1 and EPO
GO:0005634	Nucleus	Cellular component	151	1.30×10⁻²	ALAD, PLXNA1, ZNF451, ZNF250, CBX2, RNF216, ITPKB, CALB2, TGFB1 and ANK1
GO:0030424	Axon	Cellular component	12	1.72×10⁻²	CDK5R1, ATAT1, STMN3, SYT11, FKBP15, LMTK3, BSN, GPER1, LDLRAP1 and KIF21B
GO:0005884	Actin filament	Cellular component	6	1.89×10⁻²	CTTN, EZR, APC2, AIF1L, FKBP15 and MYO9B
GO:0005886	Plasma membrane	Cellular component	115	3.45×10⁻²	KCNC1, SLC9A8, ALPPL2, PLXNA1, ATP1B2, EFNA2, C6ORF25, FGFRL1, GRIK5 and TLR6
GO:0048471	Perinuclear region of cytoplasm	Cellular component	23	4.02×10⁻²	CDK5R1, ACHE, STC2, APC2, CSF1, BRSK2, VPS53, MYO9B, GPER1 and NDOR1
GO:0001228	Transcriptional activator, activity RNA polymerase II transcription regulatory region sequence-specific binding	Molecular function	8	8.50×10⁻³	MAF, MAFF, DLX2, MAFB, FOXF1, TP53, NEUROD2 and ARID3B
GO:0046872	Metal ion binding	Molecular function	68	8.68×10⁻³	GNAZ, STEAP3, SGSH, ALPPL2, ALAD, ZNF451, SOBP, ZNF250, RNF216 and ZEB1
GO:0000978	RNA polymerase II core promoter proximal region sequence-specific DNA binding	Molecular function	17	1.37×10⁻²	FOXL2, TBX15, NACC2, TBX2, MAFB, NR6A1, ARID3B, FOSB, NPAS4 and DDN
GO:0048495	Roundabout binding	Molecular function	3	1.90×10⁻²	MYO9B, TGFB1I1 and TPBGL
GO:0003779	Actin binding	Molecular function	14	1.90×10⁻²	KCNMA1, DIXDC1, FMNL3, CLMN, MYO9B, SHANK3, TNS4, EPB41L1, EZR and PACRG
GO:0030295	Protein kinase activator activity	Molecular function	4	2.46×10⁻²	DUSP19, MADD, RPTOR and EPO
GO:0098641	Cadherin binding involved in cell-cell adhesion	Molecular function	14	2.58×10⁻²	EPS15L1, SFN, SLC9A3R2, TNKS1BP1, PAK6, CTTN, EPB41L1, EZR, FASN and SPTBN1
GO:0016874	Ligase activity	Molecular function	13	3.31×10⁻²	DTX3L, PPIL2, ZNF451, RNF216, ZNRF1, TTLL11, RNF165, NEURL1B, PELI2 and NEDD4L
GO:0030276	Clathrin binding	Molecular function	5	3.75×10⁻²	TOM1L2, SYT11, RPH3AL, C2CD4C and LDLRAP1
GO:0004314	[acyl-carrier-protein] S-malonyltransferase activity	Molecular function	2	4.81×10⁻²	MCAT and FASN
hsa04910	Insulin signaling pathway	KEGG pathway	8	2.79×10⁻³	CBLB, SOS1, PRKAB2, MAPK8, RPS6KB1, SOCS4, PRKACB and PPARGC1A
hsa04068	FoxO signaling pathway	KEGG pathway	7	1.01×10⁻²	NLK, SOS1, PRKAB2, MDM2, FBXO32, MAPK8 and FOXO3
hsa04931	Insulin resistance	KEGG pathway	6	1.62×10⁻²	RPS6KA2, PRKAB2, MAPK8, RPS6KB1, OGT and PPARGC1A
hsa05205	Proteoglycans in cancer	KEGG pathway	8	1.98×10⁻²	CBLB, CTTN, ERBB4, SOS1, MDM2, RPS6KB1, PRKACB and FZD4
hsa04012	ErbB signaling pathway	KEGG pathway	5	3.14×10⁻²	CBLB, ERBB4, SOS1, MAPK8 and RPS6KB1
hsa04010	MAPK signaling pathway	KEGG pathway	8	6.08×10⁻²	RPS6KA2, ARRB1, NLK, SOS1, FGF13, MAPK8, PRKACB and MAP3K13
hsa00410	β-Alanine metabolism	KEGG pathway	3	6.72×10⁻²	ALDH6A1, ALDH1B1 and EHHADH
hsa00512	Mucin type O-Glycan biosynthesis	KEGG pathway	3	6.72×10⁻²	GALNT4, GALNT18 and B4GALT5
hsa04920	Adipocytokine signaling pathway	KEGG pathway	4	7.13×10⁻²	PRKAB2, MAPK8, PPARGC1A and CAMKK2
hsa04917	Prolactin signaling pathway	KEGG pathway	4	7.13×10⁻²	SOS1, MAPK8, SOCS4 and FOXO3

Only 10 genes were listed as examples in each pathway. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; MAPK, mitogen-activated protein kinase; FoxO, Forkhead box O.

Table V

PANTHER pathway analysis of potential target genes of miR-663a-5p and miR-154-3p in pancreatic cancer.

miRNA	Geneset	Description	Count	P-value	E	Overlapping genes	URL
miR-663a-5p	P00037	Ionotropic glutamate receptor pathway	3	0.0852	1.05	GRIK5, SLC1A7 and SHANK3	http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P00037
	P02743	Formyltetrahydroformate biosynthesis	1	0.1319	0.14	MTR	http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P02743
	P04392	P53 pathway feedback loops 1	1	0.1319	0.14	TP53	http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P04392
	P00012	Cadherin signaling pathway	6	0.1412	3.56	PCDHA8, CDH23, WNT7B, FZD1, FZD4 and CELSR1	http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P00012
	P05726	2-arachidonoylglycerol biosynthesis	1	0.1522	0.16	DAGLA	http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P05726
	P00020	FAS signaling pathway	2	0.1614	0.72	DFFB and FADD	http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P00020
	P00029	Huntington disease	5	0.1702	2.96	ARL4C, DLG4, GRIK5, PACSIN1 and TP53	http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P00029
	P00057	Wnt signaling pathway	9	0.2380	6.84	APC2, PCDHA8, CDH23, TP53, WNT7B, FZD1, FZD4, KREMEN1 and CELSR1	http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P00057
	P00045	Notch signaling pathway	2	0.2383	0.93	HEYL and HES2	http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P00045
	P02746	Heme biosynthesis	1	0.2467	0.28	ALAD	http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P02746
miR-154-3p	P00032	Insulin/IGF pathway-MAPK kinase/MAPK cascade	3	0.0116	0.48	RPS6KA2, RPS6KB1 and SOS1	http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P00032
	P06959	CCKR signaling map	7	0.0231	2.92	FOXO3, CXCL2, PRKACB, MAPK8, RPS6KB1, SOS1 and TAC1	http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P06959
	P04372	5-Hydroxytryptamine degradation	2	0.0351	0.30	ALDH1L2 and ALDH1B1	http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P04372
	P00018	EGF receptor signaling pathway	5	0.0398	1.92	ERBB4, MAPK8, SOS1, CBLB and PHLDB2	http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P00018
	P00048	PI3K pathway	3	0.0420	0.78	FOXO3, RPS6KB1 and SOS1	http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P00048
	P04397	p53 pathway by glucose deprivation	2	0.0467	0.35	PRKAB2 and RPS6KB1	http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P04397
	P00041	Metabotropic glutamate receptor group I pathway	2	0.0594	0.40	GRIN2A and PRKACB	http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P00041
	P00001	Adrenaline and noradrenaline biosynthesis	2	0.0733	0.45	SLC6A19 and SLC6A15	http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P00001
	P00035	Interferon-γ signaling pathway	2	0.0781	0.47	SOCS4 and MAPK8	http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P00035
	P00058	mRNA splicing	1	0.0808	0.08	SNRNP40	http://www.pantherdb.org/pathway/pathwayDiagram.jsp?catAccession=P00058

miR, microRNA; MAPK, mitogen-activated protein kinase; PI3K, phosphoinositide 3-kinase; IGF, interferon growth factor; CCKR, classical gastrin cholecystokinin receptor.

Table VI

ceRNAs and their sequences of miR-663a-5p and miR-154-3p.

miRNA	ceRNA	Sequences
miR-663a-5p	hsa_circ_0003176	5′-ACATGGAGCTGCACAGAATGTCAAGAATGCAAAGAGCAGAACCTTGCGCGGGCACAGGGC-3′
	hsa_circ_0048579	5′-TTCCTTAGGTTACAAAACAAAACAGGGAGAGAAAAAGCAAGTTCTCCGGGGCTTGGCGTA-3′
	hsa_circ_0063706	5′-ACTGGTCAAGTGAGTGACCTGCAGGAAGAAGGCAAGAATGCCATCAACTCACCGATGTCC-3′
	hsa_circ_0071922	5′-GACCTCTGTTGTACCTGTAATAAATATATAGAAAAAGCAAACACATACACCAATGCGGAT-3′
	hsa_circ_0078989	5′-TGTGGATGCTGTCAAACTGGGTCTACCGATTCTTCGCTGCTGCTGCCTTACCGCCGAGAA-3′
	hsa_circ_0079319	5′-TTGTCAAGTGTCAATAAAAGCATCATGTAATTTACCGAACGCCCGCAGCAGGGTCAGAAG-3′
	hsa_circ_0083080	5′-TGCATTCATTTTTTACTTTTATTAAAGGTTCAAAACCAACACGCCCCTGGGCGGTGCGCG-3′
	hsa_circ_0089643	5′-CGTCACGGCGCGCTACTACGGGAAGTCGCTGCCGTTCGGTGCGCAGTCCACGCAGCGCGG-3′
	hsa_circ_0090372	5′-AGCACCTAATTAAAGGGGCTGAAAGTCTGAGCTCTGGCCGGCCCCGGCGATTGGTCACCG-3′
	RP11-59C5.3	5′-CTTGTTTGTGCCAGGGAAAGATGGAAAATTTTAGTTTATATTAAACACGCCTTTGAAGAC-3′
	RP13-516M14.8	5′-AAACACCTGTCAGATTTCTAAGACCTGAAGCCTTGAGAAAGCATCGAAAAGTATTCAAGT-3′
	RP11-196G18.24	5′-CGCTACATAGTACGTATTATGACCAATGGATATCATTCAGAGTTCTAGTTTACATATGCT-3′
	AJ006995.3	5′-GGGAACAATTTATCTATGTTAAAAAGATGTGTGTGTGTGAATGGATGTATATACGTGTGC-3′
	AC024560.2	5′-TCACCGTGAAATATCTTCTGAGACACAACAATCTCCCTGAATTAAAACTACAGACTCTAA-3′
	PPP1R1C	5′-ACTTTTCTGAGTATACCATGGAATTCCACTGCTTGACTTCCAGAAGCATCCTCCATCTCT-3′
	LINC00595	5′-GCTGGCATCTAACGGCTTTTGTTAATTACTATATCCCAAAGAAAATGAAATAAAGGAGGG-3′
	HAGLROS	5′-GAAGTAGGCTAAGACTGCTGTTGAACTTGAAGCTAAACTTGAATGCCATTTAAAATAACA-3′
miR-154-3p	hsa_circ_0000156	5′-TGCTTTCAAGAATCATAGTGAAAGATTCGTTTTCATTGCAGAGTGGTATGATCCAAATGC-3′
	hsa_circ_0004089	5′-CACCTGCAGTAGGAAAAAGAAGCAACTAACAAAACACTGTGATAATAAGGATTATTCAGT-3′
	hsa_circ_0006461	5′-GTATGATGACATCATCCCCCCGAAGGAGTGGAAGCCGCGGCAGACGTATGATGACATCGA-3′
	hsa_circ_0015157	5′-GGAAAGAAAAAATCATAGTGAAAGATTCGTTTTCATTGCAGAGTGGTATGATCCAAATGC-3′
	hsa_circ_0038665	5′-TAAAAAATGTTTGGAGTGTAAATATACTGATGATAATGCTCTGATTCCTAAGAATTCTTC-3′
	RP11-686O6.1	5′-CCCTGCTTATGATGTAAAAATGGAGGCAGAAGACCTAAATCTAAGGCAATATACAATTTA-3′
	LINC01140	5′-CAGATGGGGTTGAAAACTCCCCTCAAAATGCAGTCTTGTTAAATTAAAAACTTGATCCAG-3′

miR, microRNA; ceRNA, competitive endogenous RNA.